University of Connecticut

OpenCommons@UConn
Doctoral Dissertations

University of Connecticut Graduate School

5-2-2017

Sickle Cell Pain Management During the First 24
Hours of Inpatient Care Compared to the National
Heart Lung and Blood Institute Clinical Practice
Guidelines for the Emergency Department: A
Quality Improvement Project
Genice T. Nelson
University of Connecticut - Storrs, genden63@gmail.com

Follow this and additional works at: https://opencommons.uconn.edu/dissertations
Recommended Citation
Nelson, Genice T., "Sickle Cell Pain Management During the First 24 Hours of Inpatient Care Compared to the National Heart Lung
and Blood Institute Clinical Practice Guidelines for the Emergency Department: A Quality Improvement Project" (2017). Doctoral
Dissertations. 1490.
https://opencommons.uconn.edu/dissertations/1490

Abstract
Sickle Cell Pain Management During the First 24 Hours of Inpatient Care Compared to
the National Heart Lung and Blood Institute Clinical Practice Guidelines for the
Emergency Department: A Quality Improvement Project
Genice T. Nelson, DNP
University of Connecticut, 2017

This quality improvement project addressed the clinical practice patterns for the first 24
hours of the hospitalized adult for inpatient care in comparison to the established
guidelines for the emergency department treatment of sickle cell pain with the NHLBI
2002 and 2013 guidelines in a suburban teaching hospital. The analysis focused on the
treatment provided which included information regarding patient assessments,
utilizations for intravenous fluids, oxygen administration, the choice of pain medications
including opioids, NSAIDS, and other adjuvants. A post hoc retrospective chart review
was conducted with data abstraction on the current clinical practice utilized during the
inpatient admission which identified deficits that will lead to the creation of a clinical
dashboard for ongoing quality improvement and outcome monitoring. This process was
guided by the principles of the Dartmouth Clinical Microsystem’s and the 5 P’s:
Purpose, Patients, Professionals, Processes, and Patterns for a complete system
change. The overall focus for change was intravenous fluids and rates, opioid titration
for pain relief, and patient reported desired pain goals.
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Chapter 1
Background of the Problem
Sickle cell disease is a lifelong, genetic, hematologic disorder in which the body
produces abnormally shaped erythrocytes (Telfair, 2003). Normal red blood cells or
erythrocytes are traditionally bi-concave discs that move easily through the blood
vessels and carry oxygen to all parts of the body (Ballas, 2005). However, “sickle cells”
are hard, sticky, and tend to clump together. The cells then get stuck and literally block
the flow of blood to the organs and limbs, causing pain, anemia, and organ damage
(Ballas, 2010). A genetic mutation in -globin gives rise to altered hemoglobin, the
oxygen-carrying molecule, found within erythrocytes. This variation has been identified
as a genetic “switch” of valine for a glutamate. This results in abnormally formed
hemoglobin, which distorts the shape of red blood cells in individuals with sickle cell
disease.
In the African American community, the incidence of sickle cell disease is
approximately 1:400 live births. The incidence of the sickle cell trait, the carrier status,
occurs in 1:12 live births, while Hemoglobin C trait occurs in 1:50, β+ thalassemia trait
occurs in 1:100, βº Thalassemia trait occurs in 1:1000, and Sickle Hemoglobin C
Disease occurs in 1:1250 (Whitten, 2001). In the United States, sickle cell disease
affects more than 100,000 people, while globally sickle cell disease affects more than
2.5 million individuals (Ballas, 2010; Hassel, 2010; Mvundura, 2009). Sickle cell disease
is common in parts of Africa, particularly Sub-Saharan Africa. Sickle cell disease is also
common in Spanish-speaking countries in South America, Central America, and parts of
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the Caribbean. In addition, sickle cell disease is prevalent in Saudi Arabia, India, and
Mediterranean countries such as Turkey, Greece, and Italy (Smith et al., 2005; Whitten,
2001).
Because of the nature of sickle cell disease as a chronic illness, the burden of
care can be tremendous on families and communities. The most common reason that
persons with sickle cell disease engage medical care and acute care services is that
they frequently suffer from vaso-occlusive crisis pain episodes (Adams-Graves, P.,
Ostric, E. J., Martin, M., Richardson, P., & Lewis, J.B., 2008). In fact, patients with sickle
cell disease utilize more emergency department services than patients with other more
common chronic illnesses such as diabetes, asthma, and hypertension (Ballas, 2009;
Ballas & Lusardi, 2005; Brousseau, Owens, Mosso, Panepinto, & Steiner, 2010; Moore,
Charache, Terrin, Barton, & Ballas, 2000). Many researchers suggest this may be
directly related to the lack of consistent care and management of adult sickle cell
disease patients in both the inpatient and the outpatient settings (Aisiku et al., 2007;
Ballas & Lusardi, 2005; Epstein, 2005).
Pain management for an adult in vaso-occlusive crisis includes the timely
administration of adequate doses of analgesia, intravenous fluids, and adjuvant antiinflammatory treatments that assist the patient to maintain a tolerable level of pain and
to function without impairment (Frei-Jones, Baxter, Rogers, & Buchanan, 2008; FreiJones, Field, & DeBaun, 2009; Lopez, Flenders, Davis-Moon, Corbin, & Ballas, 2007).
Guidelines specific to the management of sickle cell pain episodes have been
developed to reduce provider bias based on race and gender of the patients and for
facilitation of equal access to quality care during a pain episode in most care settings
2

including the home, primary care/out-patient, and emergency department. However,
these guidelines do not extend to the in-patient setting (Benjamin et al., 1999; NHLBI,
2004; Platt et al., 2002; Rees, 2003).
Purpose of Practice Change
A quality improvement project to identify and enhance key clinical practices in a
vaso occlusive crisis of an adult with sickle cell disease was conducted. The pain
episode treatments during the initial 24 hour period of hospitalization were compared to
the NHLBI emergency department guidelines. The literature currently does not include
data that compares inpatient management of adults with acute SCD pain during the
first, critical 24 hours with the NHLBI emergency department management guidelines.
This project compared inpatient clinical practice patterns in a single setting to the
most current (2002) NHLBI emergency department guidelines. Clinical practice pattern
deficits were identified in order to test and refine dashboard measures: patient
assessments, utilization of intravenous fluids, oxygen administration, and choice of pain
medications including opioids, NSAIDS, and other adjuvants to be tracked over time.
The clinical dashboard is a provider tool to monitor patient care. The clinical dashboard
was the measure to monitor high quality care and guide clinical practice patterns based
on these identified clinical practice deficits. The dashboard enabled the clinical practice
changes required to correct these deficits to remain easily identified and correctable
with systematic monitoring over time. The measures identified were used to
recommend microsystems change using the Dartmouth model.
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The following questions were addressed for each unique individual hospital
admission during the preceding one year:
1. What are the differences between clinical management approaches within the
first 24 hours of inpatient admission at the facility and the national NHLBI
standards’?
2. What are the quality improvement outcomes that need to be tracked over time to
evaluate the closure of identified practice gaps?
Significance of Project
The mental and physical challenges of acute and chronic pain coupled with other
psychosocial issues can become overwhelming and difficult to navigate for patients and
families (Aisiku et al., 2007; Bediako, Lavender, & Yasin, 2007; Jenerette & Murdaugh,
2008). Likewise, the uniqueness, complexity, and variability of sickle cell pain in adults
with SCD make its management very challenging for providers. Pain management for
an adult in vaso-occlusive crisis includes the timely administration of adequate doses of
analgesia, intravenous fluids, and adjuvant treatments that assist the patient to maintain
a tolerable level of pain and to function without impairment (Frei-Jones, Baxter, Rogers,
& Buchanan, 2008; Frei-Jones, Field, & DeBaun, 2009; Lopez, Flenders, Davis-Moon,
Corbin, & Ballas, 2007). One of the identified barriers to quality pain management for
adults listed in the American Pain Foundation Revised Pain Care Bill of Rights as cited
by the Journal of Pain and Palliative Care Pharmacotherapy (Anonymous, 2004) is that care
providers often mistrust the patients and characterize patients’ behavior as “drugseeking.” Similar barriers have been documented in adults with SCD (Ballas, 2010).
According to Ballas and Lusardi (2005), judgmental providers – nurses and medical
4

staff – were more likely to provide suboptimal pain management. Yet, for individuals
with sickle cell disease, the management of acute pain episodes that require hospital
treatment is an important aspect of their care. It is the responsibility of providers to
remove the labels of “drug-seeking” and “drug-abusers” and provide non-judgmental
care for sickle cell disease patients (Ballas & Lusardi, 2005, Maxwell, 1999).
Guidelines specific to the management of sickle cell pain episodes have been
developed to facilitate equal access to quality care during a pain episode in all care
settings including the home, primary care/out-patient, emergency department, with the
exception of in-patient (Benjamin et al., 1999; NHLBI, 2002; Platt et al., 2002; Rees,
2003 ). Limited guidelines are widely available for the management of sickle cell
disease acute care. Rees (2003) emphasizes the utilization of identification cards with
baseline information of individualized care for the cardholder, expressing the need for
urgency and expediency in care management for adults and children. The National
Institute for Health and Clinical Excellence, 2012 (NICE) has a similar individualized
patient care focus with the difference being based on patient reporting, which should
include: frequent assessments, consideration of sickle cell complications while
managing pain, and following the local protocols for management for the individual
across the lifespan. The existing NHLBI (2002) guideline for pain management in the
emergency department for hospitalized adults with sickle cell disease has specific
recommendations for treatment shown in Table 1.
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Table 1. NHLBI SCD Vaso-Occlusive Management Recommendations
Assessment and Reassessments: for the individual’s pain episode
Initial rapid assessmentof acute painful episode
including pain intensity,
prompt treatment and
relief.

Reassessments –
frequent reassessments
every 15-30 minutes after
the administration of pain
medications for pain
intensity, relief, mood, and
sedation level.

Response to therapy –
reported reduction in pain
intensity of at least 5060% from the upper end
of pain score.

Add 20 mEq KCI/L
adjusted for serum
chemistries.

Total fluids not to exceed
1.5 times maintenance
dose.

Intravenous hydration:
Initial fluid should be 5%
dextrose + half-normal
saline.

Administration of Oxygen: 2 liters via nasal cannula for patients with pulse oximetry
of 92-95%
Administration of Opioids and Adjuvants: Short-acting opioid agonists
For adults with ≤ 50 kg body weight:

For adults with ≥ 50 kg body weight:

Morphine: 0.1-0.15 mg/kg every 2-4
hours (parenteral); 0.30 mg/kg every 3-4
hours (oral).

Morphine: 5-10 mg every 2-4 hours
(parenteral);
10-30 mg every 3-4 hours (oral).

Hydromorphone: 0.015-0.020 mg/kg
every 3-4 hours (parenteral); 0.06-0.08
mg/kg every 3-4 hours (oral).

Hydromorphone: 1.5 mg every 3-4 hours
(parenteral); 7.5 mg every 3-4 hours
(oral).

*Meperidine: not recommended

Oxymorphone: 1.0-1.5 mg every 6hours
(parenteral) or 0.5 mg IV and cautiously
titrate upward. *Meperidine: not
recommended

Other routes of administration: Subcutaneous (for the individual with poor or no
venous access to prevent delays in treatment) and patient controlled analgesia
(PCA).
Non-steroidal anti-inflammatory drugs (NSAIDS):
Ketorolac (parenteral) for inadequate analgesia after optimal titration or when the side
effects of opioids are problematic (maximum use of 5 days/month).
Note. NHLBI Guidelines 2002
6

There have been a limited number of studies which demonstrated that
implementing clinical practice guidelines for the inpatient adult with sickle cell disease
could provide consistent quality care with positive patient outcomes (Adams-Graves,
Lamar, Johnson, & Corley, 2008; Ballas & Lusardi, 2005; Givens et al., 2007). AdamsGraves (2008) created a disease-specific, inpatient hospital care unit within the confines
of an academic teaching hospital, with the primary purpose of caring for adult sickle cell
patients. This disease-specific unit was intended to improve care management of
adults experiencing vaso-occlusive pain episodes or other complications of sickle cell
disease. Ballas and Lusardi (2005) developed disease specific treatment guidelines to
provide optimal management patients with SCD in the hospital setting. Increased
utilization of the existing guidelines or their adaptation would be one approach to assure
equal access to the evidence-based treatment guidelines and improve care for this
patient population given the pain episodes that are endured. Repeated pain episodes’
prompt adults with SCD to be hospitalized multiple times. An adult inpatient hospitalized
with vaso-occlusive crisis episode pain stays for an average of 6.5 days (AdamsGraves, 2008; Epstein et al 2006). Utilization of these clinical practice guidelines could
potentially reduce the number of hospital days, decrease the cost of care, increase
patient satisfaction, improve quality of life, and improve overall pain management
(Adams-Graves et al., 2008; Frei-Jones et al., 2009).
Theoretical Framework
Kolcaba (2001) stated comfort has many aspects and domains. The nurse’s goal
is to create and maintain a holistic environment and atmosphere in which patients can
recover and maintain optimal health. Comfort for many is more than just the absence of
7

pain. It is the maintenance of a nurturing, caring, and stable environment that allows the
patient to have access to the medications and treatments that will alleviate pain and
other complications in a manner that allows them to flourish in their comfort which was
used as the theoretical framework for this quality improvement project.
The Dartmouth Clinical Microsystem (2005), a systematic approach for quality
improvement, was used as the methodology to guide the project. The Dartmouth
Clinical Microsystem (2005) aided in the assessment of the current clinical practice
patterns in comparison to the NHLBI guidelines: via post-hoc medical record review,
determining themes from the data abstraction, global aim, and/or specific aims for
improvement as determined by the data analysis, and the need to change ideas with
education for the staff, patient, and/or other stakeholders to implement quality
improvement initiatives. The use of the Dartmouth Clinical Microsystem helped to
assess the current state of the clinical practice patterns by utilizing the following
characteristics known as the “5P’s”:
1. Purpose- set goals for the program to specifically improve the quality of
care and reduce pain as expeditiously as possible for the hospitalized
adult experiencing a vaso-occlusive pain event.
2. Patients- utilize patient characteristics and demographics to determine
how best to involve the patients in the quality improvement (QI) process.
3. Professionals- determine team member roles, work hours, satisfaction,
and then optimize roles for improving the quality of care for patients
hospitalized with vaso-occlusive pain.
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4. Processes-Identify the daily nursing processes for the care of these
patients during the initial 24 hours of hospitalization? What are the usual
processes?
5. Patterns- Evaluate potential daily interruptions? What are the similar
concerns or questions of the patients? When does the team meet? What
are possible outcomes? These are key components that will be
addressed with the creation of the dashboard for monitoring this QI
project.
Summary of Chapter
Sickle cell disease a genetic hematologic red blood cell disorder causes severe pain
and organ damage that leads to frequent episodic pain requiring medical intervention
(Ballas & Lusardi, 2010 & Odesina et al., 2010). Considered a rare disease in the
United States, globally approximately 2.5 million more people are affected with the
disorder (Ballas, 2010; Hassel, 2010; Mvundura, 2009). This chronic disorder has the
highest utilization of services, as measured against other chronic disorders such as
diabetes and hypertension (Ballas, 2009; Ballas & Lusardi, 2005; Brousseau, Owens,
Mosso, Panepinto, & Steiner, 2010; Moore, Charache, Terrin, Barton, & Ballas, 2000).
One of the most important aspects and ultimate goals of pain management is to
adequately relieve pain, or alleviate pain to a tolerable level (Adams-Graves et al.,
2008; Ballas & Lusardi, 2010; Brousseau et al., 2010; Frei-Jones et al., 2008; NHLBI,
2002; Odesina et al., 2010; Smith et al., 2005 ). Determining clinical practice pattern
deficits to test and refine dashboard measures (patient assessments, utilization of
intravenous fluids, oxygen administration, and choice of pain medications including
9

opioids, NSAIDS, and other adjuvants) to be tracked over time provided the foundation
for refining clinical practice patterns and the overall improvement of pain and comfort for
patients.
This quality improvement project was focused on evaluating the clinical practices to
improve inpatient pain management using the Dartmouth Clinical Microsystem. Many
researchers have suggested treatment guidelines would aid in the management of the
hospitalized adult. A methodical literature review was conducted to guide the clinical
practice pattern data abstraction for pertinent information to guide quality improvement
recommendations and the clinical dashboard for monitoring ongoing clinical practice
improvements.

10

Chapter 2
Literature Review
Introduction
This quality improvement project helped to identify current clinical practice
patterns and determined what and where practice changes were needed to foster
evidence-based practice for improved management of sickle cell pain in the inpatient
setting during the initial 24 hours of hospitalization. This review included a
comprehensive search of Medline, Cinahl, AHRQ Guidelines, DynaMed, Google
Scholar, and the Cochrane Library.
The keywords used to search the databases included sickle cell, pain
management, protocols, pain crisis, sickle cell disease clinical practice guidelines,
evidence-based clinical practice guidelines for the treatment/management of sickle cell
pain, sickle cell disease pain management, care of the adult with sickle cell disease,
pain management for adults with sickle cell disease, sickle cell disease protocols, pain
crisis guidelines for sickle cell disease, sickle cell treatments, quality improvement for
sickle cell disease management, and sickle cell practice patterns. Of the 85 listings that
were retrieved from published studies during the time span of 1985-2015, 21 studies
met the inclusion criteria. Criteria for a study to be included as part of this systematic
review were: the study needed to focus on persons with confirmed diagnoses of sickle
cell disease; and/or the management or treatment of persons in vaso-occlusive crisis;
and/or the study had to discuss the utilization of information regarding hospital or
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emergency department use, self-care and management of sickle cell disease, and
access to treatment for management of sickle cell vaso-occlusive episodes.
Of the published literature, only one of the studies, a randomized controlled trial,
met the inclusion criteria as the gold standard for research. The number of peer
reviewed, randomized controlled, or quantitative studies available in the literature is
limited to one for adults. This limitation suggests the need for continuing research that
may improve the quality of care for individuals seeking treatment for vaso-occlusive pain
episodes.
A methodical review of the literature was conducted to determine the scope of
literature available regarding clinical practice patterns for the hospitalized adult with
sickle cell disease experiencing a vaso-occlusive crisis pain episode. No research
currently exits that compares inpatient management of adults with acute SCD pain
during the first, critical 24 hours with the NHLBI emergency department management
guidelines.
Research was limited regarding clinical practice guidelines for the care of the
adult hospitalized and experiencing a vaso-occlusive crisis pain episode. The following
review includes several aspects of care: psychosocial issues of SCD, mortality/morbidity
of SCD, provider knowledge, clinical practice patterns, utilization of services, financial
burden of care, average length of stay (ALOS), and clinical practice guidelines and
protocols. This information was utilized for determining the current clinical practice
patterns for the hospitalized adult experiencing a sickle cell vaso-occlusive crisis pain
episode.
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Pathophysiology of Vaso-Occlusive Crisis Pain Episodes
The latest evidence available suggests that sickle cell vaso-occlusive crisis pain
episodes are the culmination of physiological processes that occur concurrently within
the body and cause the individual to suffer varying degrees of pain (Ballas, 2010;
Newcombe, 2002). With the occurrence of low oxygen, the red blood cells undergo
polymerization, which causes the cells to become rigid and deforms the cell membrane.
The polymerization has a domino effect, initiating a myriad of processes characterized
by an inflammatory process, which in turn creates a complex sickling deluge. This
deluge includes the dehydration of the red blood cells, which in turn creates an
irreversible sickling of the red blood cells, hemolysis which leads to anemia, and
vasoconstriction caused by nitric oxide depletion. The outcome from these cyclical
events is vaso-occlusion, which causes pain from the underlying ischemia related to the
occlusions and also causes a depletion of oxygen from the tissues. This cascade of
events can then lead to organ damage (Claster, 2003; Field, Knight-Perry, & Debaun,
2009; Platt, Eckman, Beasley, & Miller, 2002).
There are many contributing factors that may trigger a vaso-occlusive crisis pain
episode, which include the following: physical and emotional stress, extreme
temperature changes, infections, and dehydration. However, some vaso-occlusive crisis
pain episodes may have no trigger or contributing factors: for example, some episodes
occur during sleep, yet physical and emotional stress, extreme temperature changes,
infections, and dehydration can also trigger vaso-occlusion while the individual is asleep
(Aisiku et al., 2007; Benjamin, Swinson, & Nagel, 2000; Dunlop, 2006; Givens,
Rutherford, Joshi, & Delaney, 2007). Vaso-occlusive crisis pain episodes can occur any
13

time of the day or night and are unpredictable by the potential for sudden onset and
varying degrees of pain intensity as experienced by the individual. This is not to say that
all episodes are spontaneous. There are some instances in which the onset of a pain
crisis can be predicted by some individuals under certain circumstances (Newcombe,
2002; Smith et al., 2008; Smith et al., 2005).
Ballas (1995) indicated that acute sickle cell crisis pain episodes evolve over four
distinctive phases: prodromal, initial, established, and resolving. The first phase, the
prodromal phase, can last from one to four days and is characterized by pain,
weakness, fatigue, and loss of appetite, with a possibility of respiratory symptoms or
fever. The initial phase (actually the second phase of the four) can overlap with the
prodromal phase and can last one to four days also, this phase is characterized by
worsening pain, irreversibly sickled cells, dense red blood cells, increased hemoglobin
distribution width (HDW), and increased red cell distribution width (RDW). The third
phase, labelled as the established phase, can last from three to six days and is
characterized by, possible leukocytosis, possible increased temperatures, increased
reticulocyte counts, elevated lactate dehydrogenase, and possible increases in C reactive protein and serum amyloid, with possible decrease in hemoglobin. The fourth
phase, called the resolving phase, can last seven to ten days and is characterized by
stabilized RDW and HDW, decrease in dense red blood cells, decrease in irreversibly
sickled cells, possible increase in plasma viscosity, increase in platelet counts, with
possible increase in fibrinogen, and erythrocyte sedimentation rates (Ballas, 1995 &
Ballas, 2007).
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Complications of Sickle Cell Disease
The many complications of sickle cell disease (SCD) may be directly correlated
to the effects of vaso-occlusive crisis pain episodes. Providers are most familiar with the
hallmark symptom, which is vaso-occlusive crisis pain. The onset of multiple ischemic
periods and the resulting occlusions force individuals with sickle cell disease to live with
a plethora of conditions related to these phenomena, which include:


chronic pain



fatigue



Priapism



renal failure



pulmonary hypertension



hypertension



neuropathy



delayed growth and puberty



strokes



cholelithiasis



retinopathy



blindness



splenic sequestration



cardiomyopathy



bacterial infections



acute chest syndrome
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avascular necrosis



leg ulcers



aplastic episodes



depression



hepatic sequestration

Often these individuals experience acute pain along with chronic pain-pain they
experience daily and these occurrences can often overlap. This makes it more difficult
for patients, and providers to distinguish the difference between the chronic and the
acute pain experienced during vaso-occlusive pain episodes (Ballas, 2010; Dunlop,
2006; Field et al., 2009; Platt et al., 2002; Wang, 2007). In recent years, Hydroxyurea
(HU) was approved for use in adults with SCD to increase the levels of their fetal
hemoglobin. The increase in fetal hemoglobin has been associated with a decrease in
the frequency of vaso-occlusive episodes, an improved mortality from acute chest
syndrome, and a decreased need for chronic blood transfusions (Ballas et al., 2006;
Steinberg et al., 2003).
Mortality/Morbidity of Sickle Cell Disease
There are many factors that affect the mortality and morbidity of the adult living
with sickle cell disease. These include: type of SCD, age, baseline hemoglobin (Hgb)
and white blood count (WBC), left ventricular function, left ventricular size, corrected QT
(QTc), tricuspid regurgitant jet velocity (TRv), and pulmonary hypertension (pHTN),
which is defined as TRv of at least 2.5m/sec (Fitzhugh et al., 2010). These factors often
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influence the research and the discussions that compare patients with sickle cell
disease and their incidence of death.
Fitzhugh et al. (2010) studied a population of 240 adult sufferers of SCD in which
43 of the subjects died during the study period. The median age for survival was 39
years for females (95% CI: 34-56), 40 years for males (95% CI: 34-48), and 40 years
overall (95% CI: 35-48). The causes of death were reported as follows: cardiac causes
for death accounted for 25.6% (11/43 patients); pulmonary, 14% (6/43 patients); other
SCD-related, 32.6% (14/43patients); unknown, 14% (6/43patients); and others
accounted for 14% (6/43 patients). More specifically, the most common causes of death
amongst the patients studied were found to be cardiac arrest, pulmonary emboli, multiorgan failure, and stroke; additional research is required to determine the necessary
treatments to prevent fatal cardiopulmonary complications (Fitzhugh et al., 2010). Other
studies concurred that individuals living with SCD, as a group, experience a significantly
shorter lifespan and have increasingly more disease-related complications that directly
affect their mortality and morbidity, such as arthritis, diabetes, heart disease, chronic
lung problems, and kidney disease (Ballas et al., 2006; Fitzhugh et al., 2010; Steinberg
et al., 2003).
Despite the many medical advances of the last 30 years, there remains a higherthan-average premature death rate for individuals living with sickle cell disease than
those without sickle cell disease (Fitzhugh et al., 2010). Another study conducted by
Ballas and Marcolina (2006), reported an average life expectancy of 45 years of age for
individuals with SCD (Ballas et al., 2006). One possible explanation for this occurrence
may be the inferred correlation between prolonged vaso-occlusive pain episodes and
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poorly managed pain, which can lead to end-organ damage (Ballas et al., 2006;
Fitzhugh et al., 2010; Steinberg et al., 2003). In recent years the cause of death and
mortality in individuals living with sickle cell disease has shifted from infectious
processes to cardiac or pulmonary complications (Ballas et al., 2006; Steinberg et al.,
2003; Fitzhugh et al., 2010). Although adults with SCD are prone to premature mortality
and increased morbidity, for children ages 6 months to 5 years with SCD mortality and
morbidity are directly correlated with decreased incidences of fatal infectious processes
prior to the implementation of antibiotic therapy (Ballas et al., 2006; Frei-Jones et al.,
2008; Steinberg et al., 2003). Further research of this nature could help tease out the
determinants of decreasing mortality and morbidity rates in adults with SCD.
Another aspect of morbidity/mortality to consider for discussion and additional
research is the correlation between poorly managed vaso-occlusive crisis pain and
organ damage. Organ damage occurs in individuals living with sickle cell disease as a
direct result of the sickling process and damage from repeated crises (Ballas et al.,
2006; Eckman, 2010; Fitzhugh et al., 2010). Researchers need to examine barriers to
the usage of Hydroxyurea (HU) among SCD patients in all age groups and the possible
effects of limiting the number of vaso-occlusive pain crisis events on organ damage,
mortality, and morbidity. As the research that was reviewed here suggests, patient
engagement and participation is needed. Likewise, it is imperative for providers to
encourage the use of HU medication to determine if less vaso-occlusive crisis leads to
less organ damage and to determine future treatment options for individuals living with
SCD. Such work has the potential to positively impact SCD patients by decreasing

18

mortality and morbidity across their lifespans (Ballas et al., 2006; Eckman, 2010;
Fitzhugh et al., 2010; Steinberg et al., 2010).
Utilization of Services
People living with sickle cell disease utilize the emergency department, inpatient
facilities, and medical offices to manage and treat acute symptoms of vaso-occlusive
pain crisis episodes that can no longer be managed at home. Vaso-occlusive crisis pain
episodes accounted for 94.6% of the hospital admissions for patients with sickle cell
disease, which usually were from the emergency department (Epstein et al., 2006). Men
represent a higher percentage of admissions than women for acute painful episodes
(56.6% versus 38.1% of total admissions); for men, the admissions were directly related
to acute painful crisis events, while women’s admissions tended to be non-crisis related
(Ballas & Lusardi, 2005). It is important to note that SCD affects men, women, and
children differently, and the responses for these individuals will be different depending
on age, severity of disease, genotype, coping skills, and a myriad of other factors such
as infection, acute chest syndrome, cardiomyopathy, and avascular necrosis.
Ballas and Lusardi (2005) conducted a study over a five-year period, in which
they reviewed the inpatient information and looked at several aspects of SCD
admissions, such as the number of patients admitted for vaso-occlusive crisis pain
episodes (a total of 136 patients admitted for 1,540 instances), and average length of
stay (ALOS), which was 7.6 days with sickle SS (Ballas & Lusardi, 2005). Admissions
other than vaso-occlusive episodes were for transfusion, surgery, complications of
pregnancy, delivery, trauma, and hemodialysis. Additionally, 37 of the admissions with
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acute vaso-occlusive episodes also had a diagnosis of acute chest syndrome (Ballas &
Lusardi 2005). Acute chest syndrome was diagnosed in 64 of the patients after
admission, with a total of 101 admissions (6.6% of all admissions) with acute chest
syndrome as a diagnosis. Additional diagnoses identified during hospitalization of
patients with acute vaso-occlusive episodes included infections, acute chest syndrome,
cardiomyopathy, and priapism (Ballas & Lusardi, 2005).
Epstein et al. (2006) reviewed 142 unique individuals’ medical records for a total
of 4,874 emergency department (ED) visits, of which 1,607 (33%) resulted in a
hospitalization, 3,267 (67%) were independent ED usage not requiring hospitalization.
These 142 unique patients were engaged in continuous service for 3-5 years, meaning
they received their hematological and primary care within this system. A total of 1,681
inpatient admissions, which comprised 95.6% of the hospitalizations, originated from the
ED (1,607/1,681). For the overall patient population studied, the means were 4.1 office
visits per year, 7.4 total ED visits per year, 4.9 independent ED visits per year, 2.7
inpatient admissions per year and 23.2 total bed days per year. The median ED usage
was only 2.5 totals, and 1.0 independent visit per year. The median admission rate was
only 1.6 admissions per year, which accounted for a median 12.8 total bed days per
year. The average length of stay was 6.8 days, with a median of 5.9 days (Epstein et
al., 2006).
Interestingly, the main difference between the patient populations was the
genotype of the sickle cell disease – homozygous sickle-S disease in the Ballas and
Lusardi (2005) study, and hemoglobin sickle-C disease in the Epstein et al. (2006)
study; however, the findings were very similar in nature. Again, it is important to note
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there were no references made to the national guideline for pain management (NHLBI,
2002) in either of these studies. These studies reviewed the practice patterns of hospital
inpatient and emergency department use and, described patterns of healthcare
utilization and frequency of vaso-occlusive episode pain admissions, within large urban
hospital settings (Ballas & Lusardi, 2005; Epstein et al., 2006).
Ballas and Lusardi (2005) identified the primary cause of hospital admissions
were for acute vaso-occlusive pain episodes. This study consisted of 136 individual
patients with an observation admission rate of 1,540 admissions during the 5-year study
period (Ballas & Lusardi, 2005). Practice patterns for utilization that were observed
included: 50% of the patients were readmitted within thirty days of discharge for vasoocclusive pain episode; 16% of all patient admissions were within 1 week of discharge
which included a higher mortality rate associated with readmission and required careful
monitoring (Ballas & Lusardi, 2005). Causes for readmission were most frequently
determined to be premature discharge, withdrawal symptoms, and new acute pain
episodes (Ballas & Lusardi, 2005). When examining this information, Ballas discovered
several factors for readmission which included high pain scores in 52 of the patients
readmitted (higher than days 7 and 8 of their previous admissions); suboptimal plan of
pain management upon discharge (patients’ opioid dose at home much lower than
hospital pain management causing either withdrawal or new acute pain episodes).
During this 5-year study, 26 (36%) of the total number of included patients died. Of the
readmitted patients, 20% died within 1 week of being hospitalized, while 14% of all
sickle cell patients died within the 5-year study period (Ballas & Lusardi, 2005). It was
noted during this 5-year period for adult patients with homozygous sickle-S disease and
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hemoglobin sickle-C disease. The emergency department was a common place for
utilization for all patients with sickle cell disease. Of these, there was a mean of 7.4
visits per patient year, of which 1/3 of the patient visits resulted in hospital admission
with the primary diagnosis of a vaso-occlusive crisis pain episode (Ballas & Lusardi,
2005; Epstein et al., 2006).
Pain scores were also evaluated as part of the equation for high re-admission
rates within this patient population, with a reasonable explanation for this occurrence
(Ballas & Lusardi, 2005). According to Ballas and Lusardi (2005), upon the first day of
admission one would predict the pain score of the individual to be at its highest, and
then decreasing during the ensuing inpatient hospital days, with a marked decrease in
the intensity of pain from the vaso-occlusive episode from day 1 (admission) to day 5 of
hospitalization. Regression analysis shows significant decrease in the pain score
between day 1 and day 8 (r² = 69%, P = 0.011); the difference was even more
significant between days 1 and 5 (r² = 94%, P = 0.007). Regression analysis between
days 5 and 8 showed no significant difference (P = 0.106) (Ballas & Lusardi, 2005).
Pain intensity scores upon admission averaged m= 8.7 ± 1.24 for n=348
measurements of pain, with a range of pain scores being 6-10, and a median pain score
of 9. Pain intensity scores at the time of discharge averaged m=6.6 ± 1.81 for n=348
measurements of pain, with a range of pain scores being 2-10, and median pain score
of 7 (Ballas & Lusardi, 2005). With each hospital day, pain intensity scores trended
downward until day 4 (day 1: n= (337) m= 8.7 ±1.17 P= <0.001 1 vs. 2-8…, day 4: n=
(264) m= 7.5 ±1.60 P= <0.025 4 vs. 5-8) (Ballas & Lusardi, 2005). Pain intensity scores
from day 5 until the day of discharge indicated a plateau in pain and were not
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considered statistically significant [Day 5: n= (240) m= 7.3 ± 1.69 NS 5 vs. 6-8] (Ballas &
Lusardi, 2005).
Several possible reasons for the moderate pain that many individuals may have
been discharged experiencing included: 1. Difference in being admitted to hematology
units and being managed by hematologist with interests in sickle cell disease. 2.
Aggressive pain management. 3. Decision by the patient to leave due to family, job, or
childcare issues. 4. Provider bias. 5. Insurance carrier rules and pressure for discharge
(Ballas & Lusardi, 2005). These are significant details that need to be addressed during
sickle cell disease care management in the adult population as these issues are less
prevalent in pediatrics.
The lack of evidence continues to make the case for improvements in care that
will lead to continuity and better quality when treating and managing patients during a
vaso-occlusive crisis pain episode. Lastly, premature discharge from the hospital or
suboptimal practice patterns of pain management upon discharge may result in
readmissions, usually occurring within a week of discharge (Ballas & Lusardi, 2005).
These studies agreed and implied the need to establish standards of care for
hospitalized SCD patients with vaso-occlusive crises, with continued research needed.
It has been suggested that personal resources may play a critical role for
improving the health status and the quality of life for those individuals living with the
chronic illness of sickle cell disease (Jenerette & Murdaugh, 2008). The discussion of
health outcomes of adults with sickle cell disease, based on their individual ability to
cope, adjust, advocate and participate in their care, is a feature that is certainly needed

23

in the navigation of this debilitating chronic illness. The lack of evidence in this area
necessitates further testing and research to fill the gap in knowledge (Bediako et al.,
2007; Edwards, Telfair, Cecil, & Lenoci, 2001; Jenerette & Murdaugh, 2008).
Along with the encouragement of active participation in care and treatment, the
adult care providers must also consider what barriers exist in creating relationships that
allow for mutual trust and respect of the provider and patient. Self-efficacy and selfmanagement needs to be encouraged and nurtured (Bediako et al., 2007; Edwards et
al., 2001; Jenerette, & Murdaugh, 2008). Self-efficacy can be a primary variable in
predicting disease symptomatology and health services utilization for adult patients with
sickle cell disease (Edwards et al., 2001). Edwards et al. (2001) reported that lower selfefficacy levels in adults coincide with more physical and psychological symptoms, more
severe SCD pain, and more frequent physician visits. Previous studies on fibromyalgia
and arthritis denote changes in self-efficacy that were more superior forecasters of
outcomes than preliminary levels of efficacy beliefs (Edwards et al., 2001). Individuals
with SCD who display higher levels of self-efficacy may also demonstrate higher levels
of physical and psychological health and lower risk for poor SCD adjustment (Edwards
et al., 2001).
Perceived stress and psychological symptoms were significantly associated with
pain severity with r values of 0.35 and 0.34, respectively (Bediako et al., 2007). In a
sample of African Americans, Bediako et al.’s (2007) study to some extent provided an
exploratory model of the confluence of racial centrality, pain, psychological symptoms,
and the correlations for pain episode frequency, and health care usage. Racial centrality
as defined by Sellers (1998), “refers to the extent to which a person normatively defines
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himself or herself with regard to race; centrality is relatively stable across situations”
(Sellers et al., 1998). According to Bediako et al. (2007), racial centrality for the purpose
of this study was defined as normative self-relevance of race. Study results determined
that both stress and mood play a role in the course of SCD vaso-occlusive pain crisis
episodes, and that stress may precipitate vaso-occlusive pain (Porter, Gil, Carson,
Anthony, & Ready, 2000). Stress and mood was shown to be significantly associated
with increases in same-day pain ratings. A significant number of painful episodes were
preceded by increases in more severe stressors at least two days prior to onset,
suggesting that stress may be a precipitating factor of SCD vaso-occlusive pain crisis
episodes (Porter et al., 2000). Mood was assessed based on positive affect (PA) that
entailed pleasant emotions like joy and happiness, while negative affect (NA) was
associated with emotions like sadness and fear (Porter et al., 2000). Mood was
included in this study since there is mounting evidence which supports chronic illnesses
impacts, pain, functional capacity and disease symptoms (Porter et al., 2000). It is also
suggested that more research should be conducted in this area (Porter et al., 2000).
Average Length of Stay
Certain chronic illnesses such as sickle cell disease have an “average” number
of hospital days associated for care and treatment. The national average for length of
stay (ALOS) for an adult inpatient with vaso-occlusive crisis is 6.5 days. However, when
the Regional Medical Center at Memphis (Tennessee) implemented an inpatient care
delivery model for sickle cell disease patients, ALOS decreased from 5.8 days in 2002
to 4.6 days in 2007 (Adams-Graves et al., 2008). The ALOS has been shown to be
decreased by the introduction of the “Day Hospital Model” and treatment protocols
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specific for the management of sickle cell disease care; these models have also created
effective treatment measures and substantial cost savings (Adams-Graves, 2008;
Jordan, 2008). Addressing clinical practice patterns deficits by implementing quality
improvements identified with the guidance of the Dartmouth Microsystem can positively
influence the ALOS. A possible reduction in the number of days away from an
individual’s “normal life” is significant benefit to the person and family and can
appreciably increase patient satisfaction.
Financial Burden of Sickle Cell Disease
An intriguing and important aspect of healthcare that should not be overlooked is
the financial burden that chronic illness bears across the lifespan. When estimating the
economic burden of illness from a health care system perspective, the Medicaid
reimbursement rates are generally used as the proxy for the actual cost of care (Kauf,
Coates, Huazhi, Mody-Patel, & Hartzema, 2009). It is difficult to estimate the overall
cost of care for the adult SCD patient, in the case of employer-sponsored and nonMedicaid patient populations.
Kauf et al. (2009) in one study sample of 4,294 patients, aggregate health care
costs usually rose with the age of the patient, from $892 to $2,562 per patient per month
in the 0-9 and 50-64 year age groups, respectively. The average cost per patient-month
was $1,389. Largely, 51.8% of care was directly related to SCD care issues; the
preponderance of which (80.5%) was directly associated with inpatient hospitalizations
(Kauf et al., 2009). Total lifetime healthcare costs can be estimated to reach as much as
$953,640 for a SCD patient at age 45. The present value of lifetime costs is $460,151.
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Median lifetime costs were estimated at $392,940 (Kauf et al., 2009). An important note
is that the burden of care in different regions may vary, but Medicaid reimbursement
remains consistent across the country.
According to Kauf et al. (2009), the “costs of care estimates are important inputs
to health care planning, research prioritization, and the economic evaluation of new
SCD treatment strategies.” Several studies reiterated some very important topics
regarding SCD. Some of these include sickle cell disease morbidity, which remains
persistently high; the need for improved treatments; interventions designed to prevent
complications; and avoidance of hospitalization; and reductions in the economic
burdens of the disease (Ballas & Lusardi, 2005; Bediako et al., 2007; Epstein, Yuen,
Riggio, Ballas, & Moleski, 2006; Frei-Jones et al., 2008; Kauf et al., 2009; Telfair et al.,
2003).
Clinical Practice Guidelines and Protocols
Several studies have addressed clinical practice pattern elements such as
treatment protocols, and/or standardized care, reduction of hospital-associated costs,
improvement of pain management as a direct effect of the standardization of care,
reduction in length of stay, patient satisfaction, and the role of the family and health care
providers for individuals that live with SCD (Adams-Graves, et al., 2008; Frei-Jones et
al., 2009; Givens et al., 2007). One of the approaches to creating more effective
treatment options and improved outcomes has been the development and
implementation of the sickle cell, hospital day unit for the provision of care for adult SCD
patients (Adams-Graves, et al., 2008).
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One example of the benefits of treatment protocols and guidelines with the
implementation of the sickle cell hospital model has been at Diggs-Kraus Sickle Cell
Center in Memphis, Tennessee (MED). This facility provides services to 450 adults with
SCD and receives an average of 2,000 visits per year. The MED serves an adult
population that is comprised of 95% over the age of 21 years, with a female population
of 53% (Adams-Graves et al., 2008). The ethnicity of this patient population is primarily
African American, except for one patient of Hispanic descent. The chief medical
requirements for admittance at the MED for individuals with SCD do not specify crisis
pain as admission criteria.
The results of creating and implementing the inpatient care model with the SCD
unit triggered a reduction in the use of the emergency department, improved SCD care,
and improved patient/family satisfaction (Adams-Graves et al., 2008). The
implementation of standardized admission orders and guidelines for inpatient
management and treatment, and the implementation of standardized treatment
protocols for the emergency department care of individuals suffering from vasoocclusive crisis pain episodes all yielded the same kind of results for individuals at acute
care facilities. Implementing the inpatient care model with the SCD unit had a positive
outcome for the care of the sickle cell patients, which was indicated with a marked
decrease in ED visits by sickle cell patients after implementation of pain management
guidelines and increasingly proactive efforts by the Hematology Clinic to bring their
patients back to the clinic and into sickle cell day hospitals (Adams-Graves et al., 2008;
Givens et al., 2007). Total hospital visits did not change significantly in any of the 4
years, (p>0.10) under comparison. Total ED visits decreased significantly over the 428

year period (p<0.001), whereas clinic visits steadily increased (p<0.001). Return visits to
the ED within 30 days also declined significantly (p<0.001) (Givens et al., 2007). Also,
the number of admissions per year and the total admissions per hospital visit declined
markedly over time in both studies. However, the total hospital admissions did not
change, but the proportion of ED visits that resulted in admission in year 1 (29%) was
significantly lower than the proportion admitted in year 2 (43%), p=0.04. Two major
causes for this change were that (a) the use of pain protocol using morphine or
hydromorphone coupled with (b) increased access to outpatient clinics decreased ED
visits, hospitalization, and also the increased utilization of a more stable primary care
clinic setting by patients with SCD (Adams-Graves et al., 2008; Givens et al., 2007).
These results demonstrate the need to continue research for improving clinical
practice and management of vaso-occlusive pain episodes of SCD. This further
stresses the importance and the need for high-quality sickle cell care and management
in inpatient and outpatient settings, both of which can enhance the quality of care,
decrease hospital-associated cost, and improve acute pain management of patients
(Adams-Graves et al., 2008; Frei-Jones et al., 2009; Givens et al., 2007). It is critical for
researchers to further explore clinical practice patterns and the impact for SCD on the
quality of pain management for all patients with chronic or recurrent pain, patient
perception of ED pain management and the relationship of non-emergency sources of
care (Givens et al., 2007).
Rees (2003) recommended a written protocol for patients admitted for vasoocclusive episode, with a multidisciplinary approach to management. According to
Rees, (2003) the following is recommended:
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Sickle cell trait is not likely to cause pain and should not be considered the
source of pain.



Identification cards with individualized treatment requirements and
baseline information should be issued to sickle cell disease patients.



Nitrous oxides can be administered while being treated in the ambulance
not to be used frequently or for more than 1 hour.



Pain medications should be administered within 30 minutes of “entering
the hospital”, with effective analgesia within 60 minutes.



Assessments of pain, respiratory rate and sedation should be assessed
“every 20minutes until pain is controlled”.



This recommendation also strongly states that Demerol/Meperidine should
not be administered for pain control in SCD patients.

The National Institute for Health and Clinical Excellence (NICE, 2012) created
guidelines for the management of acute painful sickle cell episodes while hospitalized
for the individual with vaso-occlusive pain episode across the lifespan which included,
children, adolescents, and pregnant women. This guideline was created to help
decrease the variability in care for the United Kingdom, and education for optimal
management. The recommendations included:


Patient centered care.



Individualized assessments-treat the pain event as a medical emergency,
ascertain which treatments worked for previous episodes, listen to the
patient.
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Assess pain and offer analgesia within 30 minutes of presentation at
hospital.



Assess and monitor blood pressure, oxygen saturation, pulse rate, and
temperature.



Properly administer medications which include opioids, and adjuvants



Frequent and ongoing assessments every 30minutes initially and at least
every 4 hours once pain relief has been achieved.



Consider acute complications: abnormal respiratory signs and symptoms,
chest pain, fever, infection, and hypoxia.



Do not administer Demerol/Meperidine.



Healthcare professionals should receive ongoing training, topics should
include: pain relief, identifying complications, and attitude and presumptions
regarding patients presenting in acute sickle cell pain.

The NICE guidelines (2012) did not make medication recommendations for the
treatment of vaso-occlusive pain for each area has locally agreed protocols that should
be followed which do included opioids, and adjuvants.
The NHLBI guideline recommendations are an important aspect of care for the
individual experiencing a vaso-occlusive crisis pain episode. The current NHLBI (2002)
emergency treatment of acute pain episode guidelines state:
Patients should undergo a thorough history and physical examination to
determine whether an illness might have precipitated the pain, so that the
cause and symptom can be treated simultaneously. Patients should be
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seen immediately by a physician if they experience severe abdominal
pain, recurrent vomiting, respiratory symptoms, neurologic signs of paresis
or paralysis, acute joint swelling, priapism, or abrupt fall in hemoglobin.
Superimposition of acute pain on chronic pain may confound assessment
and treatment.

All patients should undergo rapid assessment with frequent reassessments for
acute pain episode. Pain management should be aggressive to relieve pain and achieve
maximum function expediently. Severe pain in SCD should be considered a medical
emergency which therefore needs prompt and timely treatment. The 2002 NHLBI
guidelines make the following recommendations for treatment:
1. Begin hydration: the initial fluid should be 5% dextrose + half-normal saline with
20 mEq KCL/L adjusted for serum chemistries.
2. Assess the cause of pain and any complications. Determine medications or
treatments taken at home, including usual drugs and dosages, and any potential
side effects during acute pain. Then use the opioid dosage which provided
adequate analgesia at a previous time engaged in care (for the patients known to
a practice with a previous treatment history).
3. Avoid intramuscular injections. However, if unable to obtain intravenous access,
the subcutaneous route for administration of opioids is effective and acceptable.
4. Frequent assessments of pain intensity, relief, mood, and sedation level are
required every 15 to 30 minutes after each dose of medication.
5. Titration to relief is an important aspect of care, regarding the nature of recurrent
pain episodes and for consistent management of acute pain episodes. Titration
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can be achieved with aggressive dosing and with frequent or close monitoring;
bolus dosing should be set at timed intervals after a loading dose, or “by the
clock” (BTC) dosing, such as morphine 4 mg every 2 hours.
6. Disposition at the conclusion of treatment must also be considered, whether an
individual is being discharged from the ED or from the inpatient setting.
Individuals need prescriptions for equivalent doses of pain medication to maintain
pain relief. However, after aggressive treatment is given and pain relief is not
achieved, inpatient admission should be considered (NHLBI, 2002).
Provider Knowledge
It has been acknowledged that the education of the health care providers is
pivotal to the success of any practice change, especially in a cohort of patients that are
deemed “chronic” or high utilizers of care (Aisiku et al., 2007; Fitzhugh et al., 2010).
There is a serious gap in the knowledge base of the providers in the area of treatment
and management of the adult in vaso-occlusive pain crisis episodes; this can certainly
be a topic for future studies, since this gap in knowledge may further prevent providers
from more rapidly responding to patients’ requests for changes to treatments and
medication regimens (Adams-Graves et al., 2008; Ballas & Lusardi, 2005; Aisiku et al.,
2009; Epstein et al., 2006). Studies have shown that individuals who are in a vasoocclusive pain crisis episode and treated in a sickle-cell specific care center have higher
patient satisfaction scores, more aggressive treatment, and improved overall pain
management when compared to individuals who receive care in non-specific treatment
centers (Adams-Graves et al., 2008; Aisiku et al., 2007; Ballas, 2010; Benjamin et al.,
2000; Field et al., 2009; Givens et al., 2007; Haywood et al., 2009; Smith et al., 2005).
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Solomon (2008) found that treatment and management of vaso-occlusive pain
crisis episodes in SCD patients were not given much attention in medical training
materials, with specific management recommendations in only “4 of 19 medical
textbooks." This study further reiterated information from similar research conducted by
Smith et al. (2005) and Benjamin et al. (2000); namely, providers of care for SCD vary
greatly in their knowledge of SCD in general and of opioid usage. They also frequently
possess possible prejudicial barriers and predetermined judgments regarding “drugseeking” behaviors of individuals with sickle cell disease in vaso-occlusive pain crisis
episodes, deeming these patients to be “frequent flyers” or “needing a fix” (AdamsGraves et al., 2008; Ballas, 2010; Benjamin et al., 2000; Smith et al., 2005; Solomon,
2008; Jordan, 2008). The pain of SCD is real and requires non-prejudicial and engaged
care providers to manage the symptomology and pain manifestations of this disease.
Studies have shown that when SCD care providers are trained to manage the health
issue, patient satisfaction and outcomes are improved – “practice makes for improved
care” (Jordan, 2008; Adams-Graves et al., 2008; Ballas, 2010; Benjamin et al., 2000;
Aisiku et al., 2007).
Clinical Practice Patterns for Treatment
Significant differences exist in the care of children and adults in vaso-occlusive
pain crisis episodes. One difference for children is that the barrier of mistrust does not
yet exist (Field et al., 2009; Jenerette & Murdaugh, 2008). Drug-seeking behaviors,
although they may exist in pediatric populations, are not treated in the same manner as
adults; the children are assessed for adequate pain management and treated
accordingly. This approach is not always extended to the adult population, where
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mistrust and judgmental care can be evident (Aisiku et al., 2007; Ballas, 2010; Ballas &
Lusardi, 2005; Givens et al., 2007).
The implementation of standardized sickle cell treatment guidelines and
protocols suggests these clinical practice recommendations may be cost saving in
nature, while reducing hospital readmission in the same population (sickle cell disease),
with patient-focused quality measures such as: reduction in pain score upon discharge,
and reduction in complications associated with admission for pain (Ballas & Lusardi,
2005; Epstein et al., 2006; Frei-Jones et al., 2009). During the evaluation of the
utilization of guidelines that were implemented overall, pain management was improved,
and admissions were decreased or made significantly shorter in a few limited practice
locations (Frei-Jones et al., 2008; Frei-Jones et al., 2009). These practice guidelines
allowed for more aggressive treatment in the emergency department, which had a
tremendous impact on the admission and readmission rate of individuals seeking
treatment for vaso-occlusive pain crisis episodes. During these studies, the patients in
the ED received treatment in a timelier fashion, and had more adequate pain
management, for example, adequate opioid dosing and use, decreased times for dose
administration, longer time with the clinician for treatment and assessment (Ballas &
Lusardi, 2005; Epstein et al., 2006; Givens et al., 2007; Frei-Jones et al., 2008; FreiJones et al., 2009).
In clinical practice patterns for children in vaso-occlusive crisis pain episodes with
standardized guidelines, similar patterns of utilization have been assessed by using
pediatric measures rather than adult measures. The participants’ pain was assessed by
the ED physician and/or the hematologist using the standard scale for children, which is
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the 0 to 5 Wong-Baker FACES scale; they rarely used the scale of 0 to 10 with children.
Other differences included the number of morphine doses received, and child’s/parent’s
comfort level (Frei-Jones et al., 2008). Patients, for whom the protocols were used,
received more doses of morphine, with significantly improved pain relief than those
individual patients with whom the protocol was not used (Frei-Jones et al., 2008). As
several studies have noted, suboptimal pain relief is addressed as an issue that needs
further investigation for the improvement of pain management for individuals who suffer
from vaso-occlusive pain episodes (Ballas & Lusardi, 2005; Epstein et al., 2006; FreiJones et al., 2008).
Studies dealing with adult inpatients in settings with clinical practice guidelines or
protocols in place versus patients that had their treatment in a general facility or a
facility that did not have clinical practice guidelines to follow had similar findings to the
previous pediatric study described (Adams-Graves et al., 2008; Aisiku et al., 2007;
Givens et al., 2007; Frei-Jones et al., 2009). Namely, patients and providers were more
satisfied with care, opioid dosing was more appropriate which improved analgesia,
medications were given in a timely fashion, and attitudes of the providers were better
concerning potentially “drug-seeking” behaviors that were often otherwise dismissed in
non-specific treatment centers (Adams-Graves et al., 2008; Aisiku et al., 2007; FreiJones et al., 2009; Givens et al., 2007; Jordan, 2008; Smith et al., 2005). A
collaborative team approach between generalists/hospitalists, continuity of care (same
provider or provider team) during and post hospitalization, and planning for care or
establishing a plan of care ought to be considered to improve the overall management
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of the sickle cell patient in vaso-occlusive crisis pain episodes (Ballas & Lusardi, 2005;
Epstein et al., 2006).
Summary of Chapter
A methodical review of the literature was completed to ascertain information
regarding utilization and impact of clinical practice guidelines in relation to the
management of hospitalized adults with sickle cell disease in vaso-occlusive crisis pain.
The research that is available is specific to either children or to the emergency
department management of adults. There is very little literature specific to the adult
inpatient population for the management and treatment of vaso-occlusive crisis pain
episodes. The minimal literature made references to improving the timeliness of
initiation of care, administering appropriate and adequate analgesia, which could
improve SCD vaso-occlusive crisis pain management, patient satisfaction, and
reduction in the number of inpatient hospital days. One of the most important
commonalities of the research was that when treatment guidelines, protocols, or
treatment plans were in place, the overall care and management of the patient suffering
from vaso-occlusive crisis episode pain showed general improvement compared to care
received in non-specific treatment facilities or from providers whose mistrust issues
could negatively impact clinical practice (Adams-Graves, P., Ostric, E. J., Martin, M.,
Richardson, P., & Lewis Jr, J. B.,2008; Ballas & Marcolina, 2006; Givens et al., 2007).
However, the protocols that have been identified in the literature did not focus
on the first twenty-four hours of admission, a critical timeframe for the resolution of
severe pain from a vaso-occlusive crisis pain episode. In addition, a specialized
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treatment protocol identified in an SCD specific facility is not available for replication in
other treatment facilities, and has not been published in the literature/research to date.
This quality improvement project addressed these gaps by comparing the current
clinical practice patterns for vaso-occlusive crisis pain management and treatment to
the NHLBI guidelines to identify optimal clinical practice patterns for the first 24 hours of
care for the hospitalized adult. Once the clinical practice deficits were identified, the
results were utilized to develop the clinical dashboard. The clinical dashboard will be
used to monitor the measures or outcomes that have been recommended for
performance and quality improvement, and will be evaluated prospectively, to improve
the quality of clinical practices and create change that will optimize the highest quality
evidenced based practice for the adult experiencing vaso-occlusive crisis pain.
The critical review of existing literature was greatly needed to help identify the
current clinical practices. The lack of research in the adult sickle cell population makes
the determination of deficits for improving the quality of care paramount for creating
evidenced based practices to guide high quality sickle cell care. The literature review
provided the foundation for this project.
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Chapter 3
Methods
Design
This was a quality improvement project that utilized a retrospective medical
record review to compare current clinical practice patterns during the first 24 hours of
inpatient and the first 24 hours of observation status care for adults admitted with a
sickle cell pain episode to current guidelines of the NHLBI for emergency department
care utilizing the Dartmouth Microsystem quality improvement initiatives. This quality
improvement project focused on data from the treatment provided within the initial 24
hours of patient hospitalization in regards to patient assessments, utilization of
intravenous fluids, oxygen administration, choice of pain medications including opioids,
NSAIDS and other adjuvants medications. This QI project identified clinical practice
patterns for adults hospitalized or on observation status for sickle cell pain and
compared the practice patterns to the NHLBI guidelines.
Setting and Sample
This quality improvement project was conducted at a suburban university health
center. The facility is a 225-bed facility in central Connecticut that provides general
acute care services and is a prominent teaching hospital in New England. Prior to this
project, a historic review of the utilization data was completed looking at the time period
from 4/1/2012-3/30/2014. There were 219 vaso-occlusive crisis admissions from
4/1/2012 through 3/30/2013 for 1988 inpatient days with an ALOS of 9.07 days, and 209
admissions from 4/1/2013 through 3/30/2014 with 974 inpatient days with ALOS of 4.66
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days (Utilization Data, 2014). In October of 2012, the facility’s Comprehensive Adult
Sickle Cell Program acquired a full team of providers to treat and manage the sickle cell
patients. The team included a full-time nurse practitioner, a full time social worker, along
with the full time registered nurse that had been with the program starting the previous
year. This enabled comprehensive care and full engagement of the team in- and
outpatient care settings with the adult sickle cell patients. The Sickle Cell
Comprehensive Care Center facility offers many services which include diagnosis of
sickle cell disease, ongoing ambulatory care and treatment, same day episode pain
management, and many other services all related to the management of sickle cell
disease.
The data source was a convenience sample of medical records for adults
admitted to the inpatient units for a vaso-occlusive crisis pain episode in the facility
during a 12-month period (January 2014-December 2014). All were ages 18 years and
older with confirmed sickle cell disease with one of the following variants: SS, SC, β+, or
βº. For the purposes of this project, the medical records were used to verify
documentation of disease with hemoglobin electrophoresis or other similar test results
for sickle S disease, sickle C disease, and sickle Thalassemia. The medical record of
the admitted adult had a primary or secondary diagnosis of acute vaso-occlusive pain
episode which required inpatient treatment or observation status for the management of
the pain episode.
All admissions were counted regardless of the number of admissions during the
one-year time period for each patient. These inpatient admissions and observation
status admissions occurred through the emergency department or direct admission. For
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the purpose of this quality improvement project, the first 24 hours of inpatient admission
was defined as the time from the patient’s documented arrival to the inpatient unit and
the proceeding 24 hours after arrival. Likewise, for the purpose of this quality
improvement project, the first 24 hours of observation status admission was defined as
the time of the patient’s documented arrival to the inpatient unit and the proceeding 24
hours after arrival, unless that admission was changed to inpatient within the 24-hour
timeframe. The following medical records were excluded from this project: individuals
who were younger than 18 years of age and/or patients’ whose admission records did
not indicate acute sickle cell pain as the primary or secondary diagnosis.
Project Instrument
Sickle Cell Audit Record Data Sheet (SCARDS)
The medical record abstraction form for sickle cell disease called the Sickle Cell
Audit Record Data Sheet (SCARDS - Appendix A) was created by the student
investigator. The SCARDS form is a compilation of information based on an Excel
spreadsheet that was used to collect information from the medical record during data
abstraction. The data collected for this project included: age, race, gender, marital
status, disease genotype, admission date and time, discharge date and time, primary
and secondary diagnosis, frequency of vital signs, including pulse oximetry and weight
(if recorded), use of oxygen (including amount and the apparatus such as nasal
cannula, oxygen mask, and/or nebulizer equipment) when pulse oximetry <96% (to
prevent further sickling and provide an oxygen rich environment to decrease pain
intensity by improving the ability of red blood cells to profuse tissues), frequency of
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assessments (as recorded in the medical record), pain intensity and timing of each
assessment, frequency of titrations (timing in relation to pain intensity score),
administration of intravenous fluids (type, rate, potassium repletion and
dosage/volume), use of opioid medications (dosage, frequency, and route of
administration: IV, SQ or via PCA), use of adjuvant medications (medication, dosage,
route, frequency and timing of the medication), home medications, oral intake, output,
allergies, and admission status of inpatient or observation.
Procedure
Institutional Review Board (IRB) approval was obtained from the hospital to
conduct this study. The quality improvement project utilized the Dartmouth Microsystem
quality improvement initiatives:
1. Collected data to determine and compare the current clinical practice patterns
of care for adults with SCD during the first 24 hours of inpatient admission
with the NHLBI emergency department guidelines which give initial
recommendations for inpatient management.
2. Collected data to determine and compare the current clinical practice patterns
of care for adults with SCD during the first 24 hours of observation status
admission with the NHLBI emergency department guidelines which give initial
recommendations for inpatient management.
3. Analyzed the data collected to determine clinical practice pattern deficits
based on the NHLBI emergency department guidelines.
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Following IRB approval, the student co-investigator formally requested a list of
patients admitted for vaso-occlusive crisis treatment during the study period. The patient
list was password-protected and secured on a password-protected and/or encrypted
device. Patient names were randomly ordered and assigned a unique identifier to
increase protection of patient identification. After randomization for the patient list each
medical record that was accessed was assigned an identifier for data collection for
example 01. The protected information was used to complete the medical record review
and data abstraction. The data sources for the retrospective medical record review were
the medical records of identified adults with SCD admitted to the hospital for either
inpatient or observation status care. Specifically, data extraction was for information
regarding the patients’ treatment for the first 24 hours of their hospitalization once
arrived to the inpatient unit regardless of admission status. The outpatient medical
record was reviewed for data not available during hospitalization including hemoglobin
genotype.
The timespan for data abstraction for each inpatient and observation status
admission was January 1, 2014 through December 31, 2014. The data abstraction form
developed by the student investigator contained the variables of interest that were
utilized to collect the data. Each inpatient or observation status admission was given a
unique sequential number identifier, such as 01, which assured patient anonymity and
de-identified data.
The completed de-identified data abstraction forms were stored securely on an
encrypted computer and an encrypted USB storage device whereby both the student
investigator and the major advisor had access to readily retrieve the stored information.
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The student co-investigator completed all data abstraction. Upon completion of data
collection from the medical records, the data were analyzed by imputing the collected
information into the statistical program SPSS. The retrospective medical record data
abstraction was based on the following variables, as recommended by the NHLBI
guidelines:


Assessment and frequent reassessment of pain in a SCD vaso-occlusive
crisis pain episode (pain score, timing).



Intravenous fluids (type/rate) and potassium repletion (if indicated),
determined by intake data.



Use of supplemental oxygen for 92-95% pulse oximetry measurements
that were recorded in the medical record as part of the completed vital
signs.



Opioids and adjuvant medications (medication, dose, route, and
frequency).

The following data were collected on paper using the SCARDS sheets: age,
gender, genotype, primary diagnosis, secondary diagnosis, vital signs frequency
including pulse oximetry measurements, intravenous access type or subcutaneous
access for the administration of medications and fluids, intravenous fluids and
medications being administered, medications administered for the first 24 hours of the
inpatient admission and observation status admission, supplemental oxygen use, and
date of admission and date of discharge. Data was inputted in the SPSS data file and
reviewed by the student co-investigator for inaccurate entries, typographical errors, and
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incorrect characters. Data documented on paper were stored in a locked file cabinet in
the student co-investigators office at the hospital with access only by the student
investigator and major advisor. This information was maintained until completion of the
quality improvement project and will be destroyed in five years from completion of the
project.
Data safety was maintained throughout the study by the student investigator, by
implementing the following procedures:


All data for were collected and entered by the student co-investigator.



Data collection sheets were locked in a cabinet until the completion of the quality
improvement project.



All data were imported directly into SPSS for analysis at the completion of
collection.

Analysis
This quality improvement project was designed to serve as baseline information
for the enhancement of current clinical practices for the hospitalized adult with a sickle
cell vaso-occlusive pain episode as recommended by the NHLBI clinical guidelines.
Descriptive statistics were used to analyze the data collected from the medical
record chart abstraction. The demographic information from the medical records
included frequencies for nominal and ordinal level measures and frequencies, means,
and standard deviations for interval and higher level measures. The study variables
listed for determining current clinical practices were also analyzed by the same
process: primary diagnosis, secondary diagnosis, vital sign frequency, intravenous
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access, intravenous fluids, opioid medications administered, adjuvant medications
administered for the first twenty-four hours of the admission and observation status, the
use of oxygen for pulse oximetry of <96%, genotype, and frequency of assessment and
reassessments were compared to the NHLBI clinical guidelines to identify practice
gaps.
A clinical dashboard was created for the quality improvement measures
recommendations after the completion of the data analysis. The clinical dashboard has
become the tool used to measure in a systematic and ongoing method the outcomes
deemed relevant to improve the overall quality of care to close the practice gaps during
the first 24 hours of the inpatient and observation status admissions. This dashboard
was created and presented to administrative leadership (nursing and medical) which
provided consensus for quality improvement.
Summary
In conclusion, this quality improvement project involved a retrospective chart
review covering a time span of 12 months at an academic suburban hospital site. The
abstracted information was used to compare clinical practices regarding the treatment
and management of the adult sickle cell patient in a vaso-occlusive pain crisis episode
while hospitalized to the national guidelines for emergency department treatment
published by the NHLBI. This quality improvement project sought information to
determine current clinical practice deficits and the institutional patterns to bring them in
line during the initial 24 hours of inpatient admission and the initial 24 hours of the
observation status admission of SCD pain events. This helped to define which clinical
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practice changes were needed to improve the overall care and management of the adult
hospitalized for a vaso-occlusive crisis pain episodes. This study provided the
necessary data for future practice and research regarding inpatient management of the
adult sickle cell patient.
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Chapter Four
Results
This chapter provides the results of the quality improvement project that utilized
a retrospective medical record review. This was a comparison of current clinical
practice patterns during the first 24 hours of inpatient and the first 24 hours of
observation status care for adults admitted with a sickle cell pain episode to current
guidelines of the NHLBI for emergency department care utilizing the Dartmouth
Microsystem quality improvement initiatives. The data presented here described the
inpatient status medical records reviewed first, followed by a description of the
observation status medical records data.
Eligible Medical Records
The total number of medical records reviewed for this post-hoc analysis was 234
records from the study period covering January 1, 2014 through December 31, 2014.
Of 234 records both inpatient/outpatient observation encounters 66 records were
excluded from this study as they did not meet the criteria of either primary or secondary
diagnosis of vaso-occlusive crisis pain. There were 117 eligible inpatient encounters for
project inclusion, and 51 outpatient observation encounters eligible for project
inclusion, which were reviewed. For the 117-inpatient encounter admissions, 112
were admissions to the Oncology Unit, 4 were admissions to the Medicine Unit, with 1
admission to the Multi-Specialty Unit. For the 51 observation encounter admissions,
forty-seven were admitted to the Oncology Unit, and the other four encounters were
admitted to the Medicine Unit.
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Demographics
The age of the individuals in the sample (N=54) ranged from 21 to 56 years of age.
The mean age was 31.08 (SD ± 9.48) years of age. Of these 54-unique medical
records n = 23 (42.6 %) were male and n=31 (57.4%) were female. A total of n=48
(88.9%) were Black or African American, n=5 (9.3%) were Hispanic/Latino, n=1 (1.9%)
was Caucasian or White. Additionally, the marital status and genotypes are displayed
for these individuals in Table 2.
Vital signs were reviewed for 168 individual encounters. 164 encounters (97.6%)
had vital signs at least every four hours as recommended by the NHLBI 2002
guidelines. An important additional assessment usually associated with vital signs
measurements included assessments for oxygen saturation rates or pulse oximetry
levels. Pulse oximetry measurements were recorded for 117-inpatient encounters. The
ranges for these measurements were 92% oxygenation to 100% oxygenation and are
described in Table 3. There was one record with undocumented data. For fifty-one
recorded pulse oximetry measurements for observation encounters with the range of
90% oxygenation to 100% oxygenation are also described in Table 3. Table 3 contains
the descriptive characteristics of the recorded pulse oximetry levels. Continuous
capnography for oxygenation was a requirement when individuals were treated with
continuous or basal rate dosing of an opioid.
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Table 2.
Demographic Information (n=54)
Demographics

n

Percentage

Gender
Male

23

42.6%

Female

31

57.4%

48

88.9%

White

1

1.9%

Hispanics

5

9.3%

Single

45

83.3%

Married

5

9.3%

Race
African American

Marital Status

Divorced

4

7.4%

Genotype
HgSS

38

70.4%

HgSC

10

18.5%

HgSB+

6

11.1%
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Table 3.
Pulse Oximetry Measurements (N = 168)
Inpatient Oximetry (n=117)
Measurements

n

90

0

92

2

93

Observation Oximetry (n=51)
%

Measurements

%____________

90

1

2.0%

1.7%

92

1

2.0%

6

5.2%

93

1

2.0%

94

8

6.9%

94

3

5.9%

95

9

7.8%

95

2

3.9%

96

9

7.8%

96

4

7.8%

97

14

12.1%

97

6

11.8%

98

19

16.2%

98

9

17.6%

99

22

19.0%

99

15

29.4%

100

27

23.3%

100

9

17.6%

No documented data 1

0

n

0.9%__________________________________________

Pain
The assessment and evaluation of pain was a crucial element for this quality
improvement project. The mean pain intensity level measured over the first 24 hours of
the inpatient admission was 7.48 with (SD±1.89). For the pain intensity of the inpatient
encounters there was one medical record noted to be missing and one medical record
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was noted to be missing for the observation encounters. There were 51 observation
encounters reviewed for pain intensity scores with the same measurement scale as the
inpatient encounters. The mean pain intensity level for the observation encounters was
7.92 with (SD ± 1.48).
Table 4.
Pain Intensity Scores
Inpatient
Pain Intensity Scores

Observation
n

Percentage

Pain Intensity Scores

n

Percentage

0

1

0.9

0

0

0.0

1

0

0.0

1

0

0.0

2

0

0.0

2

0

0.0

3

1

0.9

3

0

0.0

4

5

4.3

4

0

0.0

5

9

7.8

5

4

8.0

6

20

17.2

6

6

12.0

7

17

14.7

7

6

12.0

8

26

22.3

8

16

32.0

9

17

14.7

9

10

20.0

10

20

17.2

10

8

16.0

No documented scores

1

1_________

Patient-reported acceptable levels of pain were also reviewed separately and were
abstracted from the medical record as “yes” and “no” responses. More than half of all
patients, regardless of hospitalization status, needed further intervention. Of 117
medical records reviewed for inpatient encounters only 28 (23.9%) had recorded
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values; the observation encounters totaling 51 had 7 (14.0%) with recorded values with
one undocumented data record.
Patient reported pain goals were recorded as part of the pain management
assessment for both the inpatient and observation encounters. The mean patient
reported pain goal for the inpatient encounters for 117 medical records reviewed was
3.0 with (SD± 2.19). The inpatient encounters had 61 (52.1%) records without data
recorded. The observation encounters for 51 medical records reviewed had a mean
patient reported pain goal of 2.5 with (SD± 2.37), with 31 records (60.8%) without data
recorded. Please refer to Table 5 for the descriptive characteristics described.
Table 5.
Patient Pain Goals
Inpatient (n=56)

Observation (n=20) _______________

Patient Desired Pain Goal

Patient Desired Pain Goal

Pain Goal

n

Percentage_______ Pain Goal

n

Percentage_______

0

15

26.8

0

8

40.0

2

2

3.6

2

2

10.0

3

15

26.8

3

2

10.0

4

11

19.6

4

5

25.0

5

3

5.4

5

0

0

6

8

14.3

6

2

10.0

7

2

3.6

7

1

5.0

Note. Data was not documented for n = 61 inpatient and 31 observation patient stays.
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Medical Interventions:
The administration of oxygen was seen more often in use in clinical practice than
pulse oximetry based NHLBI, 2002 recommendations for indicated use with the
reference range of 92-95% for supplemental oxygen. Of the 117 inpatient medical
records reviewed n=56 (47.9%) reported the use of oxygen. Of the 51-observation
status, medical records reviewed n=20 (39.2%) reported the use of oxygen.
The management of vaso-occlusive pain episodes required the use of intravenous
fluids for hydration and to decrease viscosity of sickling blood, which is part of the
pathophysiology of a vaso-occlusive pain episode. There are many different types of
intravenous fluids readily available for administration during medical care. For the
euvolemic patient the goal of maintaining homeostasis dictates the intravenous fluid to
be administered. The NHLBI 2002, recommends the sickle cell patient be given as “the
initial fluid 5 percent dextrose and half-normal saline”. The most commonly
administered intravenous fluids used in clinical practice during the first 24 hours of
inpatient and the first 24 hours of observation status care for adults admitted with a
sickle cell pain episode to current guidelines of the NHLBI were noted here.
Per the NHLBI recommendations the IVF of choice was D5 NS 0.45% which as
described here was underutilized in both inpatient and observation encounters. There
was a total of 6 encounters in which no IVF was administered; the medical records did
not indicate why fluids were not administered as recommended by the NHLBI, 2002.
The three most commonly used intravenous fluids administered are described here in
Table 6.
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Table 6.
Intravenous Fluids
IVFs (Inpatient)

n

%

IVFs (Observation)

D5 NS 0.45%

46

40.0

D5 NS 0.45%

NS 0.9%

19

16.5

NS 0.45%

50

43.5

No documented data 2

n_

%

___

21

44.7

NS 0.9%

7

14.9

NS 0.45%

19

40.4

____________No documented data

4

___

For the 117-inpatient encounter, medical records reviewed the mean intravenous
fluid (IVF) rate was 110mL/hour with (SD ± 25.85). The range for the intravenous fluids
administered was minimum IVF rate was 50mL/hour with a maximum of 175mL/hour.
For the 51 observation encounter medical records reviewed the mean IVF rate was
110mL/hour with (SD ± 25.29). The range for the intravenous fluids administered was
minimum IVF rate was 50mL/hour with a maximum of 175mL/hour, which was the
similar findings for the inpatient encounters. For the medical records reviewed
regardless of hospital status based on weight the maintenance dose is 2-3 liters per
day for IVFs administered, IVFs rates were determined less than adequate in 59% of
the inpatients and 47% of the observation patients and are described in Table 7.
Table 7.
Intravenous Fluid Rates
Adequate Rate (Inpatient)

n

%

Adequate Rate (Observation)

Yes

46

39.3

Yes

21

41.2

Too low

69

59.0

Too low

24

47.1

Too much

0

0

Too much

2

3.9

Not administered

2

1.7

Not administered

4

7.8__
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n

%__

One of the treatment recommendations from the NHLBI, 2002 is the appropriate
assessment and intervention of potassium repletion based on blood chemistry
analyses. Of the 168 medical records reviewed which included 117 inpatient and 51
observation encounters there was a very small percentage of encounters with recorded
potassium repletion, which was appropriate based on serum chemistry results for each
encounter within the first 24 hours of either the inpatient admission or observation
status encounter. Of the 117-inpatient status encounters there were 105 (89.7%)
inpatient encounters without potassium repletion being administered, while 9 (7.7%) did
receive intravenous potassium repletion; 3 (2.6%) received 20 milliequivalents (mEq) of
potassium and 6 received 40 mEq of potassium. There were 3 (2.6%) inpatient
encounters with no documented data. Of the 51 observation status encounters 50
(98%) had no documentation of potassium repletion with 1 (2%) having documentation
of potassium repletion of 40 mEq based on laboratory chemistries.
Opioids are one of the main clinical practice cores of pain management in sickle
cell disease. The recommendation from the NHLBI (2002) is that “pain management
should be aggressive to relieve pain and achieve maximum function expediently.”
Severe pain in SCD should be considered a medical emergency which therefore needs
prompt and timely treatment:
1. Begin hydration: the initial fluid should be 5% dextrose + half-normal saline with
20 mEq KCL/L adjusted for serum chemistries.
2. Assess the cause of pain and any complications. Determine medications or
treatments taken at home, including usual drugs and dosages, and any potential
side effects during acute pain. Then use the opioid dosage which provided
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adequate analgesia at a previous time engaged in care (for the patients known to
a practice with a previous treatment history).
3. Avoid intramuscular injections. However, if unable to obtain intravenous access,
the subcutaneous route for administration of opioids is effective and acceptable.
4. Frequent assessments of pain intensity, relief, mood, and sedation level are
required every 15 to 30 minutes after each dose of medication.
5. Titration to relief is an important aspect of care, regarding the nature of recurrent
pain episodes and for consistent management of acute pain episodes. Titration
can be achieved with aggressive dosing and with frequent or close monitoring;
bolus dosing should be set at timed intervals after a loading dose, or “by the
clock” (BTC) dosing, such as morphine 4 mg every 2 hours.
6. Disposition at the conclusion of treatment must also be considered, whether an
individual is being discharged from the ED or from the inpatient setting.
Individuals need prescriptions for equivalent doses of pain medication to maintain
pain relief. However, after aggressive treatment is given and pain relief is not
achieved, inpatient admission should be considered (NHLBI, 2002).
Of the 117 medical records reviewed with inpatient status the standard of care for most
commonly used opioid was hydromorphone 99 (84.6%) with morphine 17 (14.5%) and
1 (0.9%) undocumented data. Of note, there was one (0.9%) record with oral
administered opioid within the first 24 hours of admission, the documented pain score
was “7” and labeled “unacceptable”. The medication documented for treatment was
Morphine 30mg immediate release tablets with two, one tablet doses given during the
first 24 hours. This was supplemented with “as necessary” (prn) Ultram for 2 doses
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during this same 24-hour period. The dosing for both medications was every four
hours. There were 2(1.8%) inpatient status encounters with no opioid pain medication
being documented for the first 24 hours of the inpatient admission. The first medical
record reviewed in which no opioid was given the patient reported pain score was
documented as “9/10” and labeled “unacceptable” for the patient. The second medical
record reviewed the patient reported pain score was “6/10” and labeled as “acceptable”
with the pain level rising to “10/10” and being changed to “unacceptable” with no opioid
medication being administered in the first 24 hours of the inpatient admission. There
was no documented explanation for the withholding of opioid pain medication in either
medical record. Both medical records had documented the use of the non-steroidal
anti-inflammatory (NSAID) drug ketorolac at least once for each in the first 2 hours.
There were 51 medical records reviewed with observation status. The standard of care
for the most commonly used opiate was hydromorphone 45 (88.2%). Table 8 contains
frequencies for cases with hydromorphone and morphine administration.
Table 8.
Opioid Medications
NHLBI Guidelines

(Inpatient) n=117

%

(Outpatient) n=51

%

Morphine

17

14.5

6

11.8

Hydromorphone

99

84.6

45

88.2

1

0.9

0

None
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0

The NHLBI 2002 guideline highly recommends opioid medication administration
with the use of patient controlled analgesia (PCA). For the medical records reviewed
for this post hoc quality improvement project PCA was the usual route of IV
administration. It was noted for the 117 inpatient status records reviewed there were 8
(6.8%) encounters where “bolus dosing” was used with the timing parameters of “every
1-4 hours’ prn”. It was also noted for the 51-observation status medical records
reviewed that there were 6 (11.8%) encounters where “bolus dosing” was used with the
timing parameters of “every 1-4 hours’ prn”. There was no identifiable documentation
for the reasons these individuals were not administered medication using PCA during
these hospital encounters.
The utilization of hydromorphone for the management of vaso-occlusive crisis pain
episodes was greater in this post hoc medical record review than the use of morphine.
To further understand the impact of these medications the contexts of the dosages the
morphine equivalents for hydromorphone as compared to morphine were calculated to
facilitate an accurate comparison of opioid utilized and administered. This calculation
was based of the recommended dosing of the NHLBI (2002). One important
difference between morphine and hydromorphone is the potency of the opioids.
Dilaudid a synthetic derivative of morphine has been estimated to be as little as one to
four times more potent and maximally one to ten times more potent than morphine
(Felden et al 2011; Myers-Glower 2013 & Gulur et al 2015). This facility’s pharmacy
parameters for the potency of Dilaudid have been utilized on a one to six ratio (Facility
Pharmacy, 2010). Of the 117 inpatient medical records reviewed during the first 24
hours of the inpatient admission the opioid mean equianalgesic dose administered for
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hydromorphone was 2.68mg (SD ± 3.31), the mean equianalgesic dose administered
for morphine was 13.04mg with (SD ± 11.84). Of the 51 observation, medical records
reviewed the mean equianalgesic dose administered for hydromorphone was 2.32mg
(SD ± 1.81), the equianalgesic dose for administered for morphine was 13.35mg (SD ±
12.13). The range of opioid administered for inpatient encounters during the first 24
hours of the admission was a minimum of 0mg to a maximum 53.33mg of morphine per
dose. The mean sum for opioid equivalent doses (both morphine and hydromorphone)
administered in the first 24 hours for the inpatient encounters was 1513.26mg. The
range of opioid equivalent doses administered for the observation encounters was a
minimum of 0.25mg to a maximum 66.66mg as morphine equianalgesic doses. The
mean sum for opioid equivalent doses administered in the first 24 hours for the
observation encounters was 681.17mg.
One of the methods utilized for the administration of opioids reviewed was patient
controlled analgesia (PCA). This study evaluated the number of doses that were
attempted hourly and the number of doses that were actually given hourly during the
first 24 hours of inpatient and the first 24 hours of observation status care for adults
admitted with a sickle cell pain episode to current guidelines of the NHLBI. There were
105 inpatient encounters reviewed with 12 encounters with no documented data. For
PCA injects attempted hourly the range was 0 to 44 attempts M=7.19 (SD ± 6.26). For
this same group the number of PCA injects delivered hourly range was 0 to 15 M=5.26
(SD ± 3.55). There were 43 observation encounters reviewed with 8 encounters with no
documented data. For PCA injects attempted hourly the range was 0 to 26 attempts

60

M=6.44 (SD ± 5.98). For PCA injects delivered hourly for observation encounters the
range was 0 to 14 delivered hourly M= 4.39 (SD ± 3.37).
Rapid titration to pain relief is one of the recommendations of the NHLBI for the
treatment of the sickle cell individual experiencing vaso-occlusive pain episode to make
the pain more tolerable and manageable while being hospitalized. It was noted that at
the facility all individuals being treated for VOC of sickle cell disease with continuous
dosing of an opioid for pain management or basal rate dosing, per hospital policy,
allowed for hourly increasing or up titration for pain (Facility policy, 2000). This titration
allows the nursing staff to assess and modestly increase opioid medications based on
patient reporting of pain and symptoms. This policy was adopted in congruence with
the NHLBI 2002 treatment recommendations. However, of the 117 inpatient encounters
reviewed, seven inpatient encounters were missing data and 103 (88%) encounters
had no increase or up titration during the first 24 hours of admission. Only 7(6%) of the
inpatient encounters had titration changes noted with only 2 (1.71%) of those changes
being increases in opioid.

For the 51 observation encounters reviewed with three

observation encounters with missing data 46 (90.2%) encounters had no increase or
up titration during the first 24 hours of admission. Only 2 (3.9%) had up titration
changes noted during the first 24 hours of admission.
The use of non-steroidal inflammatory medications (NSAIDS) is strongly
recommended by the NHLBI during the first 24 hours of inpatient and the first 24 hours
of observation status care for adults admitted with a sickle cell pain episode. Of the 117
inpatient medical records reviewed the use of non-steroidal anti-inflammatory
medications (NSAIDS) were used primarily for an indication of pain as noted for 72
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(61.5%) inpatient encounters with 45 (38.5%) inpatient encounters with no documented
data. The number of NSAIDS doses given ranged from 1 dose to 4 doses, M = 2.07
(SD ± 0.86). For the inpatient medical records reviewed the most commonly used
NSAID was ketorolac and route of administration are described in Table 9. Of the 51
observation, medical records reviewed the use of non-steroidal anti-inflammatory
medications (NSAIDS) were used primarily for an indication of pain as noted for 23
(45.1%) medical records with 28 (54.9%) medical records with no documented NSAID
administration. The number of NSAIDS doses given ranged from 1 to 4 doses on
average with M = 1.87 (SD ± 1.01). For the observation encounters the most commonly
used NSAID was ketorolac and route of administration is described in Table 9.
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Table 9.
Non-Steroidal Anti-inflammatory Drugs
NSAIDS

Dosage

Interval

Ketorolac

15mg-30mg

Every 6 hours

Ibuprofen

400mg-800mg

Naprosyn

500mg

Route

Oral
No documented data
Doses Administered

(Inpt) n

%

(Outpt) n

%

72

100

24

100

Every 4-6 hours

0

0

0

0

Every 12 hours

0

0

0

0

%______

______

(Inpatient) n
IV

(Inpt) n

%

Outpt)n

67

93.1

22

95.7

5

6.9

1

4.3

45

0

28

0

%

(Outpt) n

%_____________

1

21

29.2

11

47.8

2

31

43.1

6

26.1

3

16

22.2

4

17.4

4

4

5.5

2

8.7

No documented data

45

0 __________28___

_0__________

The use of adjuvants is also strongly recommended by the NHLBI during the first 24
hours of inpatient and the first 24 hours of observation status care for adults admitted
with a sickle cell pain episode. Of the 117 inpatient medical records reviewed,
adjuvants were used to help manage symptoms related to pain management such as
opioid induced pruritus and nausea. The indications are described in Table 10 as noted
for 76 medical records reviewed and 41 records with no documented data. The
number of adjuvant doses given ranged from one to nine doses, M = 1.80 (SD ± 2.95).
Of the 51 observation, medical records reviewed, 23 had no documented data. Their
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indications are described in Tables 10 and 11 respectively. The range of adjuvant
doses given was from one to ten doses on average with M=1.93 (SD ± 3.34). Adjuvant
administration is described in Table 10 (Inpatient encounters) and Table 11
(Observation encounters).
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Table 10.
Inpatient Adjuvants
Adjuvants

Dosage

Interval

n

percentage

Indication

n

(%)__

Benadryl

25mg-50mg

4-6 hours

45

59.2

Pruritus

44

57.9

Atarax

25mg

4-6 hours

1

1.3

Pruritus

1

1.3

Zofran

4mg-8mg

4-6 hours

16

21.1

Nausea

16

21.1

Baclofen

10mg

8 hours

2

2.6

Spasms

2

2.6

Lyrica

50mg-600mg

12 hours

4

5.3

Pain

4

5.1

Neurontin

100mg-900mg 8-12 hours

3

3.9

Pain

3

4.1

Ativan

0.25mg-1mg

5

6.6

6

7.9

6-12 hours

No documented data

Anxiety

41

66 ____

Route

n

IV

19

24.7

Oral

58

75.3

No documented data

40

Number of Doses Administered

Percentage ___________

_________________
n

Percentage__________

1

29

39.2

2

21

28.2

3

9

12.2

4

7

9.5

5

3

4.1

6

4

5.4

7

1

1.4

No documented doses

43

______________
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Table 11.
Observation Adjuvants

Adjuvants

Dosage

Interval

n

(%)

Indication

n

(%)_

Benadryl

25mg-50mg

4-6 hours

17

60.7

Pruritus

17

60.7

Atarax

25mg

4-6 hours

1

3.6

Pruritus

0

0

Zofran

4mg-8mg

4-6 hours

5

17.9

Nausea

5

17.9

Baclofen

10mg

8 hours

0

0

Spasms

0

0

Lyrica

50mg-600mg

12 hours

1

3.6

Pain

1

3.5

Neurontin

100mg-900mg

8-12 hours

1

3.6

Pain

1

3.5

Ativan

0.25mg-1mg

6-12 hours

3

10.6

Anxiety

4

14.4

No documented doses

23

23________

Route

n

IV

8

28.6

Oral

20

71.4

No documented data

23

Number of Doses Administered

Percentage _________________

_
n

____________________
Percentage__________

1

10

35.7

2

13

46.4

3

3

10.7

4

0

0

5

1

3.6

6

0

0

7

1

3.6

No documented doses

43

______________
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Summary of chapter
The NHLBI guidelines comparison to determine clinical patterns during the first 24
hours of the inpatient admission clearly determined clinical practice pattern deficits in
these dashboard measures: patient assessments, utilization of intravenous fluids,
oxygen administration, and choice of pain medications including opioids, NSAIDS, and
other adjuvants. Deficits were found for IV hydration and the selection of the
recommended fluid, the titration of opioid medications to pain relief and inclusion of
patient desired pain goals for the treatment of vaso-occlusive pain treatment during the
first 24 hours of hospitalization regardless of inpatient or observation status.
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Chapter Five
Discussion
Oxygenation, Pain Intensity Scores, and Patient Pain Goals
The results of this post hoc medical review indicated that the health center nursing
providers had a high rate of adherence with taking and recording vital signs for
individual patients. Of the 168 encounters reviewed, 90% of the patients had vital
signs done every four hours which is a reasonable expectation for general care
(NHLBI, 2002). The results from this post-hoc medical record reviewed were divided
into two categories. The first category was a representation of the inpatient status for
medical records with 117 encounters and the second category was a representation of
the observation status with 51 encounters.
For this project study period the recording of oxygen saturation rates were very
consistent for both the inpatient and observation status encounters. With the average
oxygenation status maintained above 90% as recommended by the NHLBI 2002
guidelines for treatment. It was unclear if oxygen was used because of low
oxygenations rates or if oxygen was placed as comfort for those individuals that
consider oxygen as “necessary” to aid in the alleviation of pain. The facility
implemented a policy in January 2010 “sickle patients that need treatment with
continuous dosing of an opioid and or basal rate are required to be maintained on
continuous capnography for oxygenation monitoring congruently with treatment.”
Limited literature is available regarding the implementation of capnography therapy,
specifically for the individual with sickle cell disease for continuous opioid
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administration. The Anesthesia Department of the hospital determined this additional
step was warranted as a safety mechanism to guard for over sedation, while traditional
use of capnography in sickle cell patients has been utilized in other instances, such as
the management of acute chest syndrome- a life threatening complication, or for a
patient that is in the intensive care hospital setting. In this instance the use of the
Dartmouth Microsystem could help to establish evidence based parameters for the
implementation for continuous capnography in the setting of continuous opioid or basal
rate administration (Dartmouth Clinical Microsystem, 2005). The Dartmouth
Microsystem could help to determine the overall process for the use of capnography
and help to clearly identify the purposes for said therapy by focusing on patient safety
and the possible reduction of over sedation. The use of capnography with continuous
opioid use for the management of vaso-occlusive crisis events of the hospitalized
patient could become more widespread thus helping to alleviate provider fears
regarding the administration of opioids and in some cases the high doses that are
required for the non-naïve opiate individual. This could be evaluated by the incidence
of the hospitalized sickle cell individual and the occurrence of over sedation events
while utilizing capnography therapy, thus, helping to establish improved care,
enhanced safety, and new evidence for creating clinical patterns of pain management.
One major limitation with the use of capnography for the measurement of
oxygenation is the non-existence of any previous literature or data available specifically
for sickle cell disease vaso-occlusive crisis pain management. The facilities’ health
program is currently demonstrating in real time the benefit of this modality as a tool in
the management of pain with continuous dosing patient controlled analgesia.
69

According to the data from this project the assessment and evaluation of pain for
the sickle cell disease adult hospitalized experiencing vaso-occlusive crisis pain the
mean intensity of pain for the inpatient encounters reviewed was 7.48 (SD±1.89) out of
10 and for observation encounters reviewed the mean pain intensity level was 7.92
(SD±1.48) out of 10. Most of the available literature discusses pain either in the
outpatient setting which includes home or the emergency department. There is limited
research that addresses the pain of the hospitalized adult whether inpatient or
observation status which is a significant limitation specifically regarding titration and
pain improvement. The presence of pain was acknowledged and consistently recorded
for both settings. The “failure” for pain management in this study is directly tied to the
very rare instances of up titration to alleviate pain. The continuous dosing of pain
medications as written by the hospital policy (2000) allows for modest increases based
on pain intensity scores. For the medical records reviewed for inpatient management
only 7 (6%) of the inpatients and 2 (3.9%) of the observation population had titration
changes with only two of those changes being increased medications for improving
pain relief.
The implementation of the Dartmouth Microsystem (2005) processes would be
utilized to reinforce and educate the nursing providers to execute established practices
and utilize processes that have been placed specifically to improve patient care, and
clinical practice. The Microsystem could be utilized to change the process if needed but
the evidence from the available data identified the process for opioid titration has not
been utilized as intended and needs to be addressed. The education for all care
providers regarding this policy could lead to improved overall pain intensity scores with
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an increase of titration for treatment in a timely manner as recommended by the
NHLBI, 2002 guidelines.
This information poses an opportunity for future studies to explore and implement
clinical practices that incorporate pain management guidelines that assist the provider
(physician or advanced practice providers) to alleviate pain with titration
recommendations written into the orders, assist the nurses to titrate according to the
orders based on the pain intensity levels, provide patient safety, reduce complications
from prolonged pain events, and increase administration of pain relieving medications,
which is ultimately more patient centered care and a higher quality of care. The
implementation of orders sets and sickle cell specific protocols for the management of
sickle cell vaso-occlusive crises pain has been recommended to promote higher quality
care and improve clinical practice patterns (Lottenberg & Hassell, 2005; Ballas, 2010;
Frei-Jones, Field, & DeBaun, 2009).
Patient reported pain goals, a critical part of the pain management assessment for
both the inpatient and observation encounters as identified in this study, had two
notable components. The first finding indicated for 52.1% of inpatient encounters and
60.8% of observation encounters no data were documented for patient pain goals.
Patient desired pain goals should be required to guide patient specific treatment. Lack
of patient pain goals can unintentionally create underutilization of needed opioids. This
can also be considered dismissive of the patients’ pain perception, which further adds
to the distrust between patients and providers (Ballas, 2010) which can lead to
ineffective treatment and prolonged pain. Successful strategies could be implemented
with the guidance of the Dartmouth Microsystem as a framework with the incorporation
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of this needed assessment information to guide clinical practice for improved and
optimal pain management. The NHLBI 2002, recommendations for rapid titration and
inclusion of previously successfully implemented treatment support the need for
obtaining this information. According to Ballas, 2005, “the patient’s self-report (of pain)
is the most important factor in the hierarchy of pain management.” The lack of this
crucial information can be akin to the rendering of suboptimal care and disbelief of the
patient’s pain experience.
A second finding for the patient reported pain goals was that many patients
recorded acceptable levels of pain less than their desired pain goals. This may require
some education on the part of the individual patient to understand the differences
between an acceptable level of pain and what a desired level of pain actually means.
Of the 117 inpatient encounters reviewed for pain goals during the first 24 hours of the
admission 56 (47%) records recorded patient reported pain goals as M=3.0 (SD ±
2.19). Of the 51 observation status encounters reviewed for pain goals during the first
24 hours of the admission 20 (37%) records with patient reported pain goals were
M=2.5 (SD ± 2.37). With the facility moving towards the implementation of the
electronic health record called Epic by the year 2018 improving this process of
determining patient pain goals could be “created as part one of the critical elements for
care during the Epic build and followed as part of the quality improvement dashboard
for improving clinical practice patterns. This would enable the recording of patient
reported goals “hardwired” as the one of the new standards for care. The creation of an
electronic template which may include “soft stops”-answer this question to continue
and/or “hard stops” you cannot move past this point without inputting information, can
72

directly improve the opportunity to meet patient expressed pain goals. This would
improve overall pain management and clinical practice patterns based on the
subjective needs of individuals being treated for vaso-occlusive pain while hospitalized
as recommended by the NHLBI 2002 guidelines. This will also allow the clinical care
team more concrete information to assist in the process of ordering and titrating opioids
to give the patient optimal analgesia.
Intravenous Fluids and Intravenous Rates
The recommended intravenous fluid to promote optimal hydration and reduce the
sickling viscosity of blood per the NHLBI 2002 guidelines is five percent dextrose and
half-normal saline. These data present an opportunity to educate care providers
regarding the utilization of hypotonic solutions such as five percent dextrose and halfnormal saline is useful because free water enters the hypertonic red blood cells,
leading to a decreased hemoglobin concentration (MCHC) and reduced red blood cell
sickling (Gavrillis & Rothenberg, 1973 & Bunn, 1997). Intravenous fluids should be
infused to correct deficits and promote euvolemic states with adequate, fluid, and rates.
The recommended intravenous fluids rates per the NHLBI 2002 guidelines should
not exceed “1.5 times maintenance (including volume for drug infusions).” For this
study the inpatient encounters IVF rate 69 (59.0 %) were less than the recommended
1.5 times the maintenance rate for IVF, none were determined to exceed the 1.5
maintenance rate with 2 encounters of no documented data. For the observation
encounters 24 (47.1%) were less than the recommended 1.5 times the maintenance
rate for IVF, 2 (3.9%) was determined to exceed the 1.5 maintenance rate and 4 (7.8%)
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encounters of no documented data. The NHLBI 2002 stresses the importance of
adequate hydration to prevent further dehydration and promote euvolemic states in
individuals experiencing vaso-occlusive pain crisis. Hydration status for individuals in
crises is an important aspect of care the affects the pathophysiologic of sickling and
dependent on clinical practice to promote hemostasis by utilizing IVF as part of the
current clinical practices of the hospitalized adult (Ballas, 2010 & Yale et al. 2000). The
recommended maintenance dose is 2-3 liters per day (Odesina 2001;SCIC 2005;Moritz
& Ayus 2015; Okomo & Meremiku 2015).
While discussing intravenous hydration potassium repletion is also recommended
by the NHLBI 2002 guidelines. There were a very small percentage of encounters with
recorded potassium repletion within the first 24 hours of either the inpatient admission
or observation status encounter. Of the 117 inpatient status encounters 105 (89.7%)
had no documentation of potassium repletion with 3 (2.6%) having no documented
data. Of the 51 observation status encounters 50 (98%) had no documentation of
potassium repletion with 1 (2%) having documentation of potassium repletion based on
laboratory chemistries. Little information regarding importance of potassium repletion
was noted in the literature although it was also discussed in the 1999, American Pain
Society guidelines for sickle cell pain management. Hypokalemia is a clinical
manifestation that may accompany sickle cell vaso-occlusive crisis as either an acute
kidney injury or cardiac dysrhythmia and should be carefully evaluated for everyone
during a vaso-occlusive crisis pain event (Jaitly et al. 2008; Epstein, 2008). This is a
limitation for this study and can be addressed in future studies.
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The Dartmouth Microsystem could be utilized to educate and monitor clinical
practice changes to ensure implementation of the recommended intravenous fluids and
the proper intravenous fluid rates are administer to optimize adequate hydration when
the adult is not able to ingest sufficient fluids. The incorporation of the “4-2-1” rule for
IVF could assist in determining the correct rates for administration of fluids based on an
individual’s weight, which has been obtained upon admission, this can further be
established with the creation of sickle cell specific protocols and order sets (Ballas,
2010; Lottenberg & Hassell, 2005; Yale et al, 2000).
Opioid Utilization
Opioids are one of the main clinical practice cores of pain management in sickle cell
disease. The NHLBI, 2002 guideline recommendations can help direct treatment and
help to improve the overall success of clinical practice in managing acute pain.
The guideline recommendations (excerpt):
Assess the cause of pain and any complications. Determine medications or
treatments taken at home, including usual drugs and dosages, and any potential
side effects during acute pain. Then use the opioid dosage which provided
adequate analgesia at a previous time engaged in care (for the patient which is
known to a practice with a previous history of treatment). Avoid intramuscular
injections. However, if unable to obtain intravenous access, the subcutaneous
route for administration of opioids is effective and acceptable. Frequent
assessments of pain intensity, relief, mood, and sedation level are required every
15 to 30 minutes after each dose of medication. Titration to relief is an important
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aspect of care, regarding the nature of recurrent pain episodes and for consistent
management of acute pain episodes. Titration can be achieved with aggressive
dosing and with frequent or close monitoring; bolus dosing should be set at timed
intervals after a loading dose, or “by the clock” (BTC-by the clock) dosing, such
as morphine 4 mg every 2 hours (NHLBI, 2002).
For this project, the most commonly utilized opioid for the inpatient encounters
was hydromorphone 99 (84.6%), with morphine 17 (14.5%) for 117 inpatient status
encounters. For the observation status encounters the opioids were utilized as follows
hydromorphone 45 (88.2%) with morphine 6 (11.8%), for 51 observation encounters.
Most encounters of the hospitalized adult for the treatment of vaso-occlusive crisis pain
received some form of opioid to treat acute pain as recommended. There was however
one (0.9%) where the opioid was administered orally. There was no documentation
why the route was not intravenous. There also were two inpatient encounters where no
opioid was administered in the first 24 hours and no documentation was available to
support this practice for the two encounters, which did not follow the treatment
recommendations for the NHLBI guidelines that opioid be given intravenous (Ballas,
2010; Lottenberg & Hassell 2005; Frei-Jones et al, 2009).
The under medicating of individuals that present for vaso-occlusive crisis pain with
the use of opioids can be directly related to provider bias and mistrust (Ballas, 2010 &
Frei-Jones et al, 2009) this issue is not unique to the hospital but to the sickle cell
community in general. This systemic problem needs to be addressed more succinctly
across the many avenues individuals with sickle cell disease may reach out to for
assistance in the management of VOC. The aid the sickle patient would require is to
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receive proper doses of medication, rapid treatment, rapid assessment, with titration of
opioids to adequately address pain (NHLBI, 2002). The Dartmouth Microsystem (2005)
can help with improving systems that can create evidenced based practices initiated
from medical record information, previous successful treatments, hematological input,
and help to eliminate provider mistrust (Dartmouth Microsystem 2005; Ballas 2010; &
Frei-Jones, Field, & DeBaun, 2009). This provider bias and mistrust does not exist in
pediatric sickle cell care and management which allows for comprehensive care,
trusting provider and patient relationships and interactions, which translates to high
quality sickle cell care (Ballas, 2010; Frei-Jones et al, 2009), which improves rapid
treatment and provides for improved opioid management during a sickle cell vasoocclusive pain event.
This project also reviewed equianalgesic dosing for opioids administered during
pain treatment of the hospitalized adult during the first 24 hours, this dosing was based
on calculations for treatment as recommended by the NHLBI 2002 guidelines noting
hydromorphone’s potency is 6 times greater than morphine (Felden et al 2011; MyersGlower 2013 & Gulur et al 2015; Facility Pharmacy, 2010). For the inpatient encounters
for hydromorphone the M = 2.68mg (SD ± 3.31), for morphine the M = 13.04mg (SD ±
11.84). For the observation encounters for hydromorphone the M = 2.32mg (SD ±
1.81), for morphine the M = 13.35mg (SD ± 12.13). Generally, opioids were
administered by using the recommended vehicle the use of PCA-patient controlled
analgesia over bolus dosing or oral administration. The opioids administered were
usually under-dosed for the management of patient pain as evidenced by documented
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self-reported high level pain scores and continued reports of unacceptable levels of
pain with opioid administration.
This study also reviewed data which observed how the PCA was utilized during the
first 24 hours of the adult patient admission. For 105 (89.7%) of the inpatient
encounters with 12 (10.3%) undocumented encounters data, the number of PCA
injects attempted hourly M = 7.19 (SD ± 6.26) with a range of 0 to 44 attempted injects
per hour. The number of PCA injects delivered for this same group was M =5.26 (SD ±
3.55) with a range of 0 to 15 injects delivered hourly. For 43 (84.3%) of the observation
encounters with 8 (15.7%) undocumented encountered data, the number of PCA
injects attempted hourly M = 6.44 (SD ± 5.98) with a range of 0 to 26 attempted injects
per hour. The number of PCA injects delivered for this same group was M = 4.39 (SD ±
3.37). Solomon, 2010 suggests that opioid administration should be dependent on
previous analgesic dosing and consider weight based dosing as recommended by the
NHLBI 2002. Several studies agree the baseline for treatment with opioids should
begin with the last previous efficacious dose if the individual in known to a practice of
facility (Ballas, 2009; Solomon, 2010, NHLBI 2002). Given the range and number of
doses attempted for both populations the recommendation of the NHLBI to titrate to
relief needs to be incorporated into any treatment regimen to improve the alleviation of
pain and the efficacy of opioid treatments. This is further evidence that the doses for
opioid given were generally seen to be less than required to provide analgesia or
adequate pain relief.
The increasing or up titration of opioid treatments was rarely observed in the data
collection of this post hoc medical record review. The hospital has included in the order
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set for PCA dosing the parameters for modestly increasing the opioid dose for an
individual in vaso-occlusive crisis pain hourly based on the patient report of pain and
symptoms. For the inpatient encounters 103 (88%) had no increase or change in
titration noted with 7 (6%) with no documented data and 7 (6%) with titration changes
but only 2 (1.7%) were increases in opioid to manage pain. For the observation
encounters 46 (90.2%) had not increase or change in titration noted with 3 (5.8%) with
no documented data and 2 (3.9%) had increases or up titration to manage pain.
One possible conclusion for nurses not implementing the ability to titrate
opioid pain medications modestly as the policy is written are the nurses concerns for
over sedation, respiratory depression, and the inability to properly assess patients in a
hectic environment of inpatient and observation hospital care along with provider bias
regarding patients reporting of pain (Bernhofer, 2011). The ability to eliminate personal
bias and judgments while providing care will allow optimal clinical practice, improved
overall pain management, and increase patient satisfaction with hospital pain
management (Dupree et al, 2009; Bernhofer, 2011, Ballas, 2010, NHLBI 2002). These
processes are not intended to discount nursing concerns for patient safety. Educating
and removing the emotionality from the process of using opioid medications especially
with the ability to modestly titrate the opioid pain medications will allow for the provision
for safe, appropriate, and humane care while providing adequate analgesia (Bernhofer,
2011 & Dupree et al, 2009). The nurse can and should practice with the autonomy the
hospital titration policy allows for to address adequate analgesia needs, and feel
comfortable with the added dimensions that will be included in the electronic medical
record as reminders of care that add to clinical practice and safety. The recruitment of
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more providers trained to manage sickle cell disease could be very impactful in the adult
population which would aid to decrease provider bias.
The use of the Dartmouth Microsystem (2005) should guide the pain management
quality improvement processes and measure the implementation and effectiveness of
the system changes. The NHLBI 2002 and the hospital 2000 treatment protocol is
already in place. The providers should be educated to use the tools in place to titrate
appropriately to alleviate pain. The facility policy can be reintroduced to the care
providers to optimize the nurses’ role to increase the medications based on the
assessment of the patient and within the ordered parameters for the individual on PCA
continuous dosing. The clinical practice patterns can be reevaluated in set time frames
to ensure the clinical processes positively impact the improvement of pain and the
overall patient reported pain scores and acceptable levels of pain. This will allow the
implementation of the recommended NHLBI 2002 as utilized by the facility to place into
practice the specific clinical practices by use of the EPIC EHR system to expand the
improvement of pain management during the first 24 hours of the inpatient
hospitalization. The inclusion or possible revision of protocols specific for sickle cell
disease management can again improve the speed of titration and quality of pain
management clinical practice patterns. This can be implemented with the introduction
of EPIC electronic health record (EHR) system in 2018, by creating sickle cell specific
templates that directly address opioid administration and the frequency of monitoring
during treatment. The nursing assessments created should specifically entail nursing
concerns with sedation levels, respiratory status, alertness, and for the patient i.e. pain
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goals, acceptable level of pain, location of pain, and patient satisfaction with care
(Dartmouth Microsystem, 2005 & Bernhofer, 2011).
NSAID and Adjuvant Utilization
The management of pain as recommended by the NHLBI 2002 should include
NSAID and adjuvants to enhance opioid use if indicated. The use of NSAIDS in this
study was primarily for the indication of pain. The most commonly used NSAID being
ketorolac for both populations. The most frequently used route for administration was
intravenously. The role of anti-inflammatory medications in the management of vasoocclusive crisis has two main functions-to help reduce the inflammation present
because of the underlying sickle cell disease and to work synergistically with opioids to
bring pain relief (APS, 1999 & NHLBI 2002).
According to the data from this study for the inpatient encounters the use of
NSAIDS was utilized for more than half of those treated for pain while in the
observation arm less than half were administered an NSAID. For both populations,
there were thirty percent or more with no documented data for this parameter of NSAID
use. Given the large percentage of undocumented data for the use on NSAIDS this has
proved to be a limitation of the project. This project showed only modest use of
NSAIDS and adjuvant therapies for the management of pain and the reduction of pain
management induced symptoms. Either the providers are unaware of the clinical
benefit the reduction of inflammation and the synergistic effect to enhance analgesia
will provide or the clinical care providers need further education regarding the benefit of
this class of medications for the use of sickle cell patients. Given the clinical benefit for
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this patient population it would be prudent to provide the basic education needed to
allow this practice to become part of the standard of care. With the impending EHR this
medication can be one of the staples for the order set or template for pain management
of the sickle patient regardless of admission status.
The use of adjuvants was primarily for symptomatic complaints such as opioid
induced pruritus or nausea. For both populations, the adjuvants were primarily
administered orally with more than fifty percent requiring medications to help combat
opioid induced pruritus. The use of adjuvant also had a large number of undocumented
data for both the inpatient and observation encounters. The most commonly prescribed
adjuvants were Benadryl and Zofran, and were proven to be effective as administered
orally. For the sickle cell patient that is receiving treatment for vaso-occlusive crisis
episode pain the anticipation of pruritus and nausea could bring the added benefit of
relief of unwanted symptoms while anticipating the relief of pain. The “hardwiring” of
these medications into a sickle cell specific order set would impact clinical practice
patterns positively and increase patient satisfaction with hospital care. This was not
congruent with several recommendations for treatment in sickle cell specific guidelines
(Ballas, 1995; NHLBI, 2002; Rees et al, 2001). Particularly the use of ketorolac has
been shown to decrease the need for utilization of opioids and enhance vaso-occlusive
crisis pain management for the sickle cell patient.
Limitations
There were limitations to this quality improvement project. This project was limited
to a small university health center with a relatively small patient sample size. The
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design for a quality improvement project was a retrospective post hoc medical record
review for a period of one full year January 1, 2014 thru December 31, 2014. The
sample for medical review had multiple encounters for several medical records. During
the data collection phase, it was noted several encounters had been admitted first as
observation and then later converted to an inpatient admission. This was addressed by
separating the different admission statuses and evaluating them separately. Patients
that had inpatient care should have improved outcomes from patients being cared for
23 hour, inpatient data would be more conservative regarding deficits. However, the
data for both patient populations had similar outcomes and deficits despite the
intervention of 23 hours of ongoing treatment prior to admission. The instrument used
for data collection was created specifically for this quality improvement project. The
instrument was modified to incorporate more data and may need to the updated and
generalized for replication for other area studies.
The age of the data could be considered a limitation of this project. The data was
abstracted for the year 2014. Although several institutional changes were made since
the data were collected inpatient care managed by the inpatient team has remained
unchanged, and therefore unlikely to impact data relevance. The data was collected by
the student investigator who was also an employee of the hospital. The potential for
bias during data collection is counterbalanced by the investigator’s expertise with the
system and institutional practices for sickle cell pain management.
It would be important for future studies to ascertain if oxygen is donned for comfort
measures or if truly deemed hypoxic. This determination may prove impactful in other
treatment areas and needs to be fully assessed to ensure if underlying pathology is
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present it can be fully and appropriately treated. The use of capnography with
continuous dosing of intravenous opioids could be a lifesaving measure and needs
further evaluation and documentation. The limitation of previously available literature
for treatment comparisons creates a unique opportunity to promote this pilot project
information to create the opportunity for change and improvement for other treatment
facilities by adjusting care parameters for opioid dosing thus increasing the ability for
opioid continuous dosing improving pain treatment overall for sickle cell patients.
Pain management for the hospitalized adult in sickle cell vaso-occlusive crisis pain
is a limitation and may not be able to generalize to other facilities. However, the
different aspects of pain management can be evaluated in other facilities and include:
the pain measurement tools, the assessment documentation, and evaluation for the
frequency of titration to analgesia-all important aspects of pain management that can
be evaluated for improvement. Paramount to this process and a limitation is the
inconsistency for determining patient desired pain goals. This information needed to
determine analgesia parameters and can be evaluated in other settings to guide the
pain protocols and help to create sickle cell specific algorithms to help patients reach
improved pain states. This should also include ensuring adequate doses of opioids are
administered and titrated for unacceptable levels of pain. Although the hospital policy
allowed for modest titration of the opioids based on the patients reported levels of pain
it was unclear why this was not carried out. The parameters were clearly listed as part
of the medication administration record. Perhaps reeducation may be required to
implement options that are available to help improve pain. Lastly, the modest use of
NSAIDS and adjuvants could be significantly improved once the reasoning is
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determined for the underutilization. This could easily be replicated at other facilities to
ensure optimization of available therapies utilized as therapeutically as indicated.
Implication for Future Studies
This quality improvement project can be replicated in different facilities across the
country to determine their clinical practice patterns for the management of sickle cell
disease within multiple settings. The evaluation of key elements can help to determine
what areas of practice need improvement and what is being done well that should be
sustained. Sickle cell patients reside all over this country and this information is
applicable to all who manage individuals living with this chronic debilitating disease.
This type of quality improvement project can help to bridge the distress that some
providers may have in regard to the self-report of patient pain without the benefit of
objective findings for acute pain management.
One of the issues that may be of interest is the use of oxygen. The use of oxygen
for many individuals experiencing sickle pain has associated comfort with this practice
for pediatric care. This can be addressed by determining true hypoxemia and the
clinical need for oxygen versus placating a request because of previous use. This
determination could be valuable in future studies regarding clinical practice patterns for
oxygenation. The proper intravenous fluid utilized for hydration is another area for
clinical practice that can be assessed and evaluated. Unless an individual being treated
is deemed to be hypovolemic then the recommendations by the NHLBI 2002 for
rehydration should be followed unless contraindicated. Rehydration should include the
parameters of fluid rates- “not to exceed 1.5 times maintenance including volume for
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drug infusions”, along with closely monitoring serum chemistries for hypokalemia and
the need for potassium repletion as needed, this was not an issue as indicted with the
data collected.
Opioid dosing should be closely evaluated and titrated appropriately to meet the
needs of the individual. This should include reviewing patient passports if available,
previous successful opioid treatments, and reliable patient reporting where applicable.
Under dosing of pain medications should be avoided to prevent untoward
complications from prolonged pain events. The use of PCAs as recommended by the
NHLBI should be utilized where available. This should also include the frequent
assessment of the patients reported pain levels, desired pain goals measurements,
and acceptable levels of pain. This should be discussed with the patient at frequent
intervals to ensure pain is improving and becoming tolerable for the patient. This
should incorporate titrating medications to meet the patient’s pain needs versus
keeping an individual on the same dose for several days with little to no improvement
which causes prolong pain, lengthens the hospital stay, decrease patient satisfaction,
and disrupts family and home lives.
Lastly incorporating the use of NSAIDS and adjuvants routinely in specific sickle cell
care can help reduce complications associated with opioid pain management i.e. opioid
induced pruritus, constipation, and nausea. For some patients being treated with
opioids, pruritus can be extremely severe and debilitating to the degree of causing
lacerations from scratching with miscellaneous objects. This side effect should not be
ignored and may not respond to Benadryl; effective treatments need to be researched
and evaluated to decrease the severity of this issue. Treatment with Naloxone has
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proven to be effective in some instances but replication of this practice is needed to
verify the efficacy of this practice. Nausea should also be treated proactively with the
use of strong opioids to prevent further dehydration which can lead to worsening
sickling. Oral administration of these medications is preferred however in the presence
of active vomiting intravenous route is acceptable. Care providers should encourage
adequate nutritional support when appropriate. Evaluating the use of these medications
can help establish improved sickle cell specific treatment guidelines and protocols for
sickle cell inpatient care with replication of use in multiple settings.
Implication for Practice
The clinical practice patterns for this quality improvement project has documented
several areas for quality improvement that will be addressed: hydration- the type of
intravenous fluids administered, titration of opioids for pain relief, and the recording of
patient desired pain goals. Hydration-for this project it was noted the recommended
IVF was underutilized five percent dextrose and half-normal saline for more than half of
the fluids administered. The use of the correct fluid is crucial for restoring homeostasis
and a euvolemic state for the individual experiencing vaso-occlusive crisis pain.
Titration for the alleviation of pain – the most important aspect of care for the individual
seeking care, rapid titration and the increase of opioid dosing is critical to pain
management and needs to happen in a timely manner with the proper assessments for
evaluation of treatment. As stated previously titration of opioids for improving pain the
hospitalized sickle cell patient for vaso-occlusive pain is critical. For patients reporting
high levels of pain in comparison to patient reported desired level for pain and or
acceptable pain levels the practice should be to increase the doses and reassessment
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until pain has improved. This can be done by giving specific parameters for increasing
opioid dosing with nursing assessments and evaluations. Modest increase can be 0.5
to 1mg. hourly to every two hours with frequent assessments especially in the patients
that are taking chronic opioids at home. Patient desired pain goals will become the
gauge for which pain management is administered and titrated.
Clinical Dashboard
The creation of the clinical Dashboard will be completed by the Facilities’ Hospital IT
Department at the direction of nursing administration and the medical director for the
Adult Comprehensive Sickle Cell Program in anticipation of the electronic medical
record program Epic 2018. The clinical Dashboard will focus on three outcomes of this
quality improvement project which has been presented to the Nursing Administration.
The three outcomes of focus:
Hydration: intravenous hydration- to follow the NHLBI recommendation of dextrose five
percent with half strength (0.45%) of normal saline, unless active vomiting is noted.
Titration: quickly administering adequate doses of pain medication to help achieve
maximal levels of comfort as quickly and safely as possible.
Patient pain goals: the accurate recording of patient reported pain goals to assist with
optimal pain relief as guidance for pain management.
A concerted effort on the part of providers will be required to create, implement and
monitor the required changes to improve the overall quality of care administered to
sickle cell adult patients. The current clinical practice patterns will be transformed to
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manage patient needs correcting the identified treatment deficits during the first 24
hours of inpatient and the first 24 hours of observation status care for adults admitted
with a sickle cell pain episode to current guidelines of the NHLBI for emergency
department care utilizing the Dartmouth Microsystem quality improvement initiatives for
populating the clinical dashboard.
The clinical dashboard will be based on information extracted from the
implementation of the electronic health record EPIC in 2018. The Epic program can be
designed to include disease specific order sets that can guide clinical practice. In
particular, the order sets for sickle cell disease management can include parameters
for intravenous hydration which includes the type of fluid and rate. An example of
disease specific sickle cell orders sets is displayed here as Exhibit A.
Exhibit A. Sickle Cell Infusion Order Set Sample

The order set can also include specific parameters for example the outpatient
treatment of a vaso-occlusive crisis episode that would be administered in the day
hospital a Sickle Cell Infusion as displayed here in Exhibit B.
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Exhibit B. SCD Order Set Sample

The creation of the Epic design has some unique features that can be capitalized upon
for each different facility to cater (attend to the needs of) to unique patient populations.
Thus, creating individualized care- creating higher quality clinical practice patterns
within disease specific protocols. These order sets can include laboratory requests and
orders for the administration of antibiotics if deemed necessary to meet an individual
patient’s clinical needs, this is displayed here with Exhibits C, D, and E.
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Exhibit C. SCD Order Set Sample A
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Exhibit D. SCD Order Set Sample B
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Exhibit. E SCD Order Set Sample C

With the use of these types of orders sets guiding clinical practice, the monitoring of the
clinical practices changes shall be simplified with collaborations between the nursing,
medical and IT departments. This would be specifically designed and guided with the
Dartmouth Microsystem (2005) with the implementation of the five “Ps.”
The actual clinical dashboard will be created by the healthcare team, patients, IT
department, and ancillary stakeholders involved with care for individuals with sickle cell
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disease. Cooperatively the clinical dashboard will be created inclusive of the different
variables of the Epic electronic medical record. The clinical dashboard will focus on the
care being monitored hydration, titration, and patient pain goals. This will aid with the
goal of visually observing the achievement of benchmarks towards improving clinical
practice and improving the quality of care. The clinical dashboard may look similar to
the example displayed here with the appropriately label interventions see Exhibit F.
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Exhibit F. Clinical Dashboard Sample
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Exhibit G. Clinical Dashboard Sample A

96

Exhibit H. Clinical Dashboard Sample B

The goal for the creation of the clinical dashboard for the hospital will be to provide
a clear picture of the care being provided using visualizations as seen in these
examples. A dashboard is utilized to convey relevant information to clinicians and
leadership in a way that communicates quantitative data that is easily understood. This
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aids in the ease of sharing information and correcting deficits. The dashboard also
allows for tracking specific measures and clinicians to own where data needs are on
track. The dashboard can also allow in an organized manner information regarding
financial, operational performance, along with clinical performance which can add to
cost saving measures. The metrics to be reviewed: hydration, titration, and patient
desired pain goals, to determine if clinical practices changes are being adhered,
exchanged- as proficiency develops to improve other clinical practices, updated as
benchmarks are met; monitoring all to ensure ongoing high quality improvements and
overall care improvements. These are important parameters that should be addressed
as part of the Epic build team for the sickle cell disease protocols.
Implication for Policy
The hospital has implemented two key policies for the care of sickle cell patient.
One of the first being the use of capnography for continuous dosing with opioids by the
pharmacy department. This policy could have long reaching implications for policies in
other facilities that may consider the use of continuous opioid dosing for sickle cell
vaso-occlusive pain as a safety and prevention measure. Determining the impact of
this policy in other locations and facilities could globally expand opioid use in pain
treatment especially with the negative connotation associated with these medications in
the media because of misuse and high profile deaths of superstars like Prince and
Michael Jackson.
The second policy allows for modest titration of an administered opioid based on
pain levels of the sickle cell patient being treated for vaso-occlusive crisis pain episode.
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This policy if followed as ordered allows the nurse to incrementally increase the dose of
opioid setting on the PCA to improve analgesia. This increase allows for slowly titrating
pain medications with nursing assessments and documentation. This also allows the
nurse to titrate down for the patient that has achieved analgesia and is ready to be
tapered down on the opioids. These changes in care for patients can be impactful by
eliminating wait time for orders and delays in treatment. These policies do not eliminate
the need for provider involvement but focus the care on getting pain under control
expeditiously. However, this policy has not improved outcomes yet. The
implementation and use of these policies will impact positively the quality of care and
improve the clinical practice patterns currently in place while improving patient
satisfaction with inpatient and observation care. The policies can easily be adopted for
use at other facilities and help provide higher quality care for the adult admitted with
vaso-occlusive crisis pain. The inclusion of the nursing leadership for the hospital
health will help push the initiative to provide high quality care, which will improve trust
and satisfaction for both the patient and the provider.
Implication for Education
The introduction of the Dartmouth Microsystem will create the opportunity to
educate the care providers, especially the nursing staff regarding clinical practice
patterns of focus-hydration, titration to pain relief, and patient desired pain goals. The
systematic approach will use the 5 P’s “purpose-, patients, professional, processes,
and patterns. The education will clarify the global aims for the quality improvement
project, for the staff (healthcare team) and other stakeholders-whom are patients, IT,
social workers, care coordinators, pharmacy and administration , and be evaluated by
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the creation of the dashboard with the implementation of the electronic medical record
Epic in 2018.

Conclusion
Sickle cell disease impacts healthcare utilization, families, and individuals living with
the disease in a fashion unlike other chronic illnesses. This quality improvement project
can have long lasting implications for improved care of the hospitalized adult, creating
evidenced based disease specific protocols that can lead to improved pain
management. This, in turn, can lead to faster recovery and departure from the hospital.
Improving titration to analgesic effect, decreasing hyper-viscosity by administering the
correct intravenous fluids at the appropriate rates, and providing adequate opioid
management to address each individual desired pain goals will ultimately impact quality
of life and function. Having a clinical dashboard to monitor and evaluate overall clinical
care patterns allows for corrective action more expediently and applauds the
continuance of meeting and exceeding clinical benchmarks visually. This project was
undertaken to improve inpatient clinical practice patterns for the hospitalized adult
during the first 24 hours of the inpatient admission. With the results and the creation of
the clinical dashboard, improvements will be achieved over time including the creation
of improved clinical practice patterns and eventually improved outcomes for the adult
with sickle cell disease.
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Appendix A
SCARDS (Sickle Cell Audit Record Data Sheet)
SICKLE CELL AUDIT RECORD DATA SHEET (SCARDS)
Medical Record Unique ID#
Date of Audit:
Gender:
□ F
□M
Age:
Race:
Ethnicity:
Genotype:
Marital Status:
□Jamaican
□Black or
□
HgSS
□Single
□Haitian
African American
□HgSC
□Married
□African
□Hispanic/Latino □Caribbean Islander
□
HgSβ+
□Divorced
□Mexican
□White
□HgSβ○
□Widowed
□Puerto Rican
□Unknown
□Columbian
□Italian
□Turkish
□Greek
□Non Hispanic/Latino

Primary Dx:
Admit Date:
T:
T:
T:
T:
T:
T:

P:
P:
P:
P:
P:
P:

Secondary Dx:
Time:
Discharge Date:
Vital Signs:
R:
R:
R:
R:
R:
R:

Oxygen: □Yes □No
Time:

B/P:
B/P:
B/P:
B/P:
B/P:
B/P:

POX:
POX:
POX:
POX:
POX:
POX:

WT:

Liters:
Apparatus: □ NC □ Mask Nebs: □Yes □No
Frequency of Assessments:

Pain Intensity:

Prompt Treatment:

Pain Relief:

Frequency of Reassessments:
Timing Q15-30:

Timing after admin of
meds:

Pain intensity:
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Relief:

Mood:

Sedation level:

Intravenous Fluids:
NS 0.9%
□Yes □No
NS 0.45%
□Yes □No
NS 0.225%
□Yes □No
Ringer’s Lactate
□Yes □No
D5 Ringer’s Lactate
□Yes □No

Amount:

Rate:

D5%W
□Yes □No
D10%W
□Yes □No
D5NS
□Yes □No
D5 ½ NS
□Yes □No
D5 1/3 NS
□Yes □No

□Yes □No
Dosage:
Opioid Administration
Adults with ≤ 50K Body Weight:
Dosage
Frequency
IV

Amount:

Rate:

Potassium Repletion

Opioid

SQ

PCA
Basal-Bolus

Morphine
Hydromorphone
Opioid

Adults with ≥ 50K Body Weight:
Dosage
Frequency
IV

SQ

PCA
Basal-Bolus

Morphine
Hydromorphone
Oxymorphone
*Meperedine
Not Recommended

Medication
Ketorolac
Motrin
Naprosyn
Benadryl
Atarax
Zofran
Muscle
Relaxants
Benzodiazepine
Allergies
Oncology 6

Dosage

Med 4

NSAIDS/Adjuvants
Route
Frequency

Location During Admission
ICU
Cardiac
Stepdown

Effects

Time

Med 5

OB

Table 1. NHLBI SCD Vaso-Occlusive Management Recommendations
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Table 1. NHLBI SCD Vaso-Occlusive Management Recommendations
Assessment and Reassessments: for the individual’s pain episode
Initial rapid assessmentof acute painful episode
including pain intensity,
prompt treatment and
relief.

Reassessments –
frequent reassessments
every 15-30 minutes after
the administration of pain
medications for pain
intensity, relief, mood, and
sedation level.

Response to therapy –
reported reduction in pain
intensity of at least 5060% from the upper end
of pain score.

Add 20 mEq KCI/L
adjusted for serum
chemistries.

Total fluids not to exceed
1.5 times maintenance
dose.

Intravenous hydration:
Initial fluid should be 5%
dextrose + half-normal
saline.

Administration of Oxygen: 2 liters via nasal cannula for patients with pulse oximetry
of 92-95%
Administration of Opioids and Adjuvants: Short-acting opioid agonists
For adults with ≤ 50 kg body weight:

For adults with ≥ 50 kg body weight:

Morphine: 0.1-0.15 mg/kg every 2-4
hours (parenteral); 0.30 mg/kg every 3-4
hours (oral).

Morphine: 5-10 mg every 2-4 hours
(parenteral);
10-30 mg every 3-4 hours (oral).

Hydromorphone: 0.015-0.020 mg/kg
every 3-4 hours (parenteral); 0.06-0.08
mg/kg every 3-4 hours (oral).

Hydromorphone: 1.5 mg every 3-4 hours
(parenteral); 7.5 mg every 3-4 hours
(oral).

*Meperidine: not recommended

Oxymorphone: 1.0-1.5 mg every 6hours
(parenteral) or 0.5 mg IV and cautiously
titrate upward. *Meperidine: not
recommended

Other routes of administration: Subcutaneous (for the individual with poor or no
venous access to prevent delays in treatment) and patient controlled analgesia
(PCA).
Non-steroidal anti-inflammatory drugs (NSAIDS):
Ketorolac (parenteral) for inadequate analgesia after optimal titration or when the side
effects of opioids are problematic (maximum use of 5 days/month).
Note. NHLBI Guidelines 2002
103

Table 2.
Demographic Information (n=54)
Demographics

n

Percentage

Gender
Male

23

42.6%

Female

31

57.4%

48

88.9%

White

1

1.9%

Hispanics

5

9.3%

Single

45

83.3%

Married

5

9.3%

Race
African American

Marital Status

Divorced

4

7.4%

Genotype
HgSS

38

70.4%

HgSC

10

18.5%

HgSB+

6

11.1%
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Table 3.
Pulse Oximetry Measurements (N = 168)
Inpatient Oximetry (n=117)
Measurements

n

90

0

92

2

93

Observation Oximetry (n=51)
%

Measurements

%____________

90

1

2.0%

1.7%

92

1

2.0%

6

5.2%

93

1

2.0%

94

8

6.9%

94

3

5.9%

95

9

7.8%

95

2

3.9%

96

9

7.8%

96

4

7.8%

97

14

12.1%

97

6

11.8%

98

19

16.2%

98

9

17.6%

99

22

19.0%

99

15

29.4%

100

27

23.3%

100

9

17.6%

No documented data 1

0

n

.9%_____________________________________
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Table 4.
Pain Intensity Scores
Inpatient
Pain Intensity Scores

Observation
n

Percentage

Pain Intensity Scores

n

Percentage

0

1

0.9

0

0

0.0

1

0

0.0

1

0

0.0

2

0

0.0

2

0

0.0

3

1

0.9

3

0

0.0

4

5

4.3

4

0

0.0

5

9

7.8

5

4

8.0

6

20

17.2

6

6

12.0

7

17

14.7

7

6

12.0

8

26

22.3

8

16

32.0

9

17

14.7

9

10

20.0

10

20

17.2

10

8

16.0

No documented scores

1

1_________
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Table 5.
Patient Pain Goals
Inpatient (n=56)

Observation (n=20) _______________

Patient Desired Pain Goal

Patient Desired Pain Goal

Pain Goal

n

Percentage_______ Pain Goal

n

Percentage_______

0

15

26.8

0

8

40.0

2

2

3.6

2

2

10.0

3

15

26.8

3

2

10.0

4

11

19.6

4

5

25.0

5

3

5.4

5

0

0

6

8

14.3

6

2

10.0

7

2

3.6

7

1

5.0

Note. Data was not documented for n = 61 inpatient and 31 observation patient stays.
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Table 6.
Intravenous Fluids
IVFs (Inpatient)

n

%

IVFs (Observation)

D5 NS 0.45%

46

40.0

D5 NS 0.45%

NS 0.9%

19

16.5

NS 0.9%

NS 0.45%

50

43.5

NS 0.45%

No documented data 2

____________No documented data
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n_

%

___

21

44.7

7

14.9

19

40.4

4

___

Table 7.
Intravenous Fluid Rates
Adequate Rate (Inpatient)

n

%

Adequate Rate (Observation)

Yes

46

39.3

Too low

69

59.0

Too much

0

0

Not administered

2

1.7
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n

%__

Yes

21

41.2

Too low

24

47.1

Too much

2

3.9

Not administered

4

7.8__

Table 8.
Opioid Medications
NHLBI Guidelines

(Inpatient) n=117

%

(Outpatient) n=51

%

Morphine

17

14.5

6

11.8

Hydromorphone

99

84.6

45

88.2

1

0.9

0

None
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Table 9.
Non-Steroidal Anti-inflammatory Drugs
NSAIDS

Dosage

Interval

Ketorolac

15mg-30mg

Every 6 hours

Ibuprofen

400mg-800mg

Naprosyn

500mg

Route

(Inpt) n

%

(Outpt) n

%

75

100

24

100

Every 4-6 hours

0

0

0

0

Every 12 hours

0

0

0

0

%______

______

(Inpatient) n
IV
Oral
No documented data

Doses Administered

%

Outpt)n

67

93.1

22

95.7

5

6.9

1

4.3

45

(Inpt) n

28
%

(Outpt) n

%_____________

1

21

29.2

11

47.8

2

31

43.1

6

26.1

3

16

22.2

4

17.4

4

4

5.5

2

8.7

No documented data

45

__________28___
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Table 10.
Inpatient Adjuvants
Adjuvants

Dosage

Interval

n

percentage

Indication

n

(%)__

Benadryl

25mg-50mg

4-6 hours

45

59.2

Pruritus

44

57.9

Atarax

25mg

4-6 hours

1

1.3

Pruritus

1

1.3

Zofran

4mg-8mg

4-6 hours

16

21.1

Nausea

16

21.1

Baclofen

10mg

8 hours

2

2.6

Spasms

2

2.6

Lyrica

50mg-600mg

12 hours

4

5.3

Pain

4

5.1

Neurontin

100mg-900mg 8-12 hours

3

3.9

Pain

3

4.1

Ativan

0.25mg-1mg

5

6.6

6

7.9

6-12 hours

No documented data

Anxiety

41

66 ____

Route

n

IV

19

24.7

Oral

58

75.3

No documented data

40

Number of Doses Administered

Percentage ___________

_________________
n

Percentage__________

1

29

39.2

2

21

28.2

3

9

12.2

4

7

9.5

5

3

4.1

6

4

5.4

7

1

1.4

No documented doses

43

_____________
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Table 11.
Observation Adjuvants

Adjuvants

Dosage

Interval

n

(%)

Indication

n

(%)_

Benadryl

25mg-50mg

4-6 hours

17

60.7

Pruritus

17

60.7

Atarax

25mg

4-6 hours

1

3.6

Pruritus

0

0

Zofran

4mg-8mg

4-6 hours

5

17.9

Nausea

5

17.9

Baclofen

10mg

8 hours

0

0

Spasms

0

0

Lyrica

50mg-600mg

12 hours

1

3.6

Pain

1

3.5

Neurontin

100mg-900mg

8-12 hours

1

3.6

Pain

1

3.5

Ativan

0.25mg-1mg

6-12 hours

3

10.6

Anxiety

4

14.4

No documented doses

23

23________

Route

n

IV

8

28.6

Oral

20

71.4

No documented data

23

Number of Doses Administered

Percentage _________________

_
n

____________________
Percentage__________

1

10

35.7

2

13

46.4

3

3

10.7

4

0

0

5

1

3.6

6

0

0

7

1

3.6

No documented doses

43

______________
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115
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